# 2025年11月15日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 勘误：eIF4E S209位点磷酸化促进myc和应激驱动的肿瘤发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236815](https://pubmed.ncbi.nlm.nih.gov/41236815)
**期刊：** eLife
**PMID：** 41236815
**DOI：** 10.7554/eLife.109900

### 第一部分 原文与翻译

**英文原标题：** Correction: eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇勘误，其订正了关于eIF4E S209位点磷酸化在肿瘤发生中作用的先前研究。从标题推断，原研究的核心在于揭示eIF4E蛋白在S209位点的磷酸化是myc过表达和细胞应激诱导癌症形成的关键“许可”信号。这一发现可能为靶向相关激酶以治疗特定癌症（如myc驱动的肿瘤）提供了新的分子靶点。然而，由于没有提供摘要，无法评估该勘误的具体内容及其对原研究结论的实质性影响。

---

## 2. 先天性免疫记忆：巨噬细胞在治疗中不断演变的作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236793](https://pubmed.ncbi.nlm.nih.gov/41236793)
**期刊：** eLife
**PMID：** 41236793
**DOI：** 10.7554/eLife.108276

### 第一部分 原文与翻译

**英文原标题：** Innate immune memory: The evolving role of macrophages in therapy.

**英文摘要原文：**
Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.

**中文摘要译文：**
训练免疫通过证明一度被认为缺乏记忆的先天免疫细胞可以被重编程，从而对后续的挑战产生更强的反应，这正在重塑我们对宿主防御的理解。与耐受、分化或启动不同，训练免疫依赖于定居的髓系细胞的表观遗传和代谢重编程，特别是在皮肤、肠道和肺等黏膜屏障中，这些细胞在这些部位提供持续的保护以抵御毒素和病原体。在此，我们综述了近期的研究进展，这些进展展示了初始刺激如何赋予单核细胞和巨噬细胞长期的功能性变化，这些变化在再次暴露时可能是有益的保护性的，也可能是不适应的。我们重点介绍了利用训练免疫来增强疫苗效力的治疗机会，并讨论了在癌症和高炎症性疾病中调节此程序的策略。最后，我们为增强或抑制训练免疫以促进人类健康提出了新的方向。

### 第二部分 AI 大师评价

这篇综述精炼地总结了“训练免疫”这一前沿领域的核心进展，阐明了巨噬细胞等先天免疫细胞如何通过表观遗传与代谢重编程获得记忆功能。文章不仅探讨了这种免疫记忆在再次暴露于刺激时所表现出的保护性与病理性双重作用，还前瞻性地讨论了其在增强疫苗效力、癌症治疗及调控高炎症性疾病中的巨大应用潜力。该综述为理解和利用先天免疫记忆提供了清晰的框架，对开发新型免疫疗法具有重要的指导价值。

---

## 3. NEDD8特异性蛋白酶1缺陷通过CAND1-NEDD8通路失调驱动肝母细胞瘤发展的新机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236496](https://pubmed.ncbi.nlm.nih.gov/41236496)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41236496
**DOI：** 10.1097/HEP.0000000000001614

### 第一部分 原文与翻译

**英文原标题：** NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.

**英文摘要原文：**
BACKGROUND AIMS: Hepatoblastoma (HB) is the most common malignant liver tumor in children. Despite advances in multimodal treatment, chemoresistance and relapses remain major clinical challenges. NEDDylation, a post-translational modification involving the ubiquitin-like molecule NEDD8, has been implicated in cancer, but its role in HB remains poorly understood. This study investigates the functional relevance of the deNEDDylase NEDP1 and its downstream target CAND1 in HB progression and therapy response.

RESULTS: Transcriptomic and proteomic analyses of HB patient samples, cell lines, Patient-Derived Xenograft (PDX) cells, and transgenic mouse models revealed a significant reduction in NEDP1 expression and activity, accompanied by global hyper-NEDDylation. Functional studies demonstrated that NEDP1 overexpression restored deNEDDylation, induced apoptosis, impaired tumor cell proliferation and metabolism, and significantly restrained tumor growth and metastasis in both in vivo mouse models and in the chorioallantoic membrane (CAM) assay. Proteomic profiling identified CAND1 as a key NEDDylated substrate regulated by NEDP1. High CAND1 expression was associated with aggressive molecular HB subtypes (C2-pure, Epi-CB) and poor clinical outcomes, including reduced overall survival. Rescue experiments confirmed that CAND1 overexpression counteracted the antitumor effects of NEDP1.

CONCLUSIONS: NEDP1 acts as a tumor suppressor in HB by modulating the NEDDylation status of key regulatory proteins, particularly CAND1. Restoration of NEDP1 activity suppresses tumorigenesis and metastasis, underscoring the NEDDylation pathway as a promising therapeutic target. CAND1 is proposed as a potential prognostic biomarker and actionable oncogenic driver in HB.

**中文摘要译文：**
背景与目的： 肝母细胞瘤（HB）是儿童中最常见的恶性肝脏肿瘤。尽管多模式治疗取得了进展，但化疗耐药和复发仍然是主要的临床挑战。NEDD8化是一种涉及泛素样分子NEDD8的翻译后修饰，已被证实与癌症相关，但其在肝母细胞瘤中的作用仍知之甚少。本研究旨在探讨去NEDD8化酶NEDP1及其下游靶点CAND1在肝母细胞瘤进展和治疗反应中的功能相关性。

结果： 对肝母细胞瘤患者样本、细胞系、患者来源的异种移植（PDX）细胞和转基因小鼠模型的转录组学和蛋白质组学分析显示，NEDP1的表达和活性显著降低，并伴有全局性的超NEDD8化修饰。功能性研究表明，过表达NEDP1可恢复去NEDD8化作用，诱导细胞凋亡，削弱肿瘤细胞的增殖和代谢，并在体内小鼠模型和鸡胚绒毛尿囊膜（CAM）实验中显著抑制肿瘤生长和转移。蛋白质组学分析鉴定出CAND1是受NEDP1调控的一个关键NEDD8化底物。CAND1的高表达与侵袭性分子亚型肝母细胞瘤（C2-pure, Epi-CB）以及包括总生存期缩短在内的不良临床结局相关。回复实验证实，过表达CAND1可抵消NEDP1的抗肿瘤效应。

结论： NEDP1通过调节关键调控蛋白（特别是CAND1）的NEDD8化状态，在肝母细胞瘤中发挥肿瘤抑制因子的作用。恢复NEDP1的活性可抑制肿瘤的发生和转移，凸显了NEDD8化通路是一个有前景的治疗靶点。CAND1被认为是肝母细胞瘤中一个潜在的预后生物标志物和可作为靶点的致癌驱动因子。

### 第二部分 AI 大师评价

本研究旨在阐明去NEDD8化酶NEDP1及其下游靶点CAND1在儿童最常见的肝脏恶性肿瘤——肝母细胞瘤（HB）中的作用机制。研究团队综合运用了转录组学、蛋白质组学及多种体内外模型，发现NEDP1在HB中发挥着肿瘤抑制因子的功能，其表达下调导致全局性超NEDD8化修饰。该研究不仅首次揭示了NEDP1通过调控其关键底物CAND1的NEDD8化状态来抑制肿瘤发生与转移的新机制，更将NEDD8化通路确立为极具潜力的治疗靶点，并提出CAND1可作为HB的预后生物标志物和治疗干预靶点，具有重要的临床转化价值。

---

## 4. 幽门螺杆菌在胃癌之外的疾病负担：量化大规模根除策略被忽视的潜在益处

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236450](https://pubmed.ncbi.nlm.nih.gov/41236450)
**期刊：** Gastroenterology
**PMID：** 41236450
**DOI：** 10.1053/j.gastro.2025.08.015

### 第一部分 原文与翻译

**英文原标题：** The Disease Burden of Helicobacter pylori Beyond Gastric Cancer: Quantifying the Forgotten Potential Benefits of Mass Eradication.

**英文摘要原文：**
BACKGROUND & AIMS: Although Helicobacter pylori screen-and-treat has demonstrated effectiveness in preventing gastric cancer (GC), the impact on other diseases, such as peptic ulcer disease (PUD), dyspepsia, and gastric lymphomas, is often overlooked in guidelines and policy-analyses. This study quantifies the disease burden attributable to H pylori beyond GC.

METHODS: A systematic literature search identified studies reporting the relative risk of developing PUD, dyspepsia, or gastric lymphomas due to H pylori to calculate the population attributable fraction (PAF) for each condition. The PAF represents the proportion of disease burden caused by H pylori. Preventable case numbers were calculated based on the risk reduction from eradication, both globally and specific for countries with varying H pylori prevalence.

RESULTS: The proportions of PUD, dyspepsia, and gastric lymphoma attributable to H pylori (95% confidence interval) were 57% (44%-68%), 7% (2%-13%), and 33% (12%-53%), respectively, corresponding to 3.5 (2.7-4.2) million, 30 (7.1-52.2) million, and 12,000 (4200-19,100) cases potentially preventable through eradication, globally. Country-specific estimates varied with lowest PAFs (PUD, dyspepsia, gastric lymphomas) observed in the United States (35% [24%-47%], 3% [2%-13%], and 17% [5%-31%]) and highest in South Korea (63% [50%-73%], 9% [2%-15%], and 39% [14%-58%]). However, even in the United States, preventable case numbers remained substantial for PUD (134,000 [93,000-177,000]) and dyspepsia (860,000 [196,000-1.5 million]).

CONCLUSIONS: Omitting PUD and dyspepsia as outcomes in studies on H pylori screen-and-treat may substantially underestimate benefits. Incorporating these diseases alongside GC into cost-effectiveness and policy analyses, therefore, may improve the evaluation of H pylori screen-and-treat programs. The actual benefit depends on the extent to which H pylori triggers an irreversible pathway to disease early in life.

**中文摘要译文：**
背景与目的：尽管幽门螺杆菌（H. pylori）筛查与治疗策略在预防胃癌（GC）方面已证实其有效性，但在相关指南和政策分析中，其对消化性溃疡（PUD）、消化不良及胃淋巴瘤等其他疾病的影响常被忽视。本研究旨在量化由H. pylori引起的胃癌以外的疾病负担。

方法：通过系统性文献检索，筛选出报告了因H. pylori感染导致PUD、消化不良或胃淋巴瘤相对风险的研究，以计算每种疾病的人群归因分数（PAF）。PAF代表了由H. pylori所致疾病负担的比例。基于根除H. pylori带来的风险降低，计算了全球范围以及不同H. pylori流行率国家的可预防病例数。

结果：归因于H. pylori的PUD、消化不良和胃淋巴瘤的比例（95%置信区间）分别为57%（44%-68%）、7%（2%-13%）和33%（12%-53%），在全球范围内，这分别对应于通过根除策略可预防的350万（270万-420万）、3000万（710万-5220万）和1.2万（4200-19100）例病例。各国的估算数据存在差异，其中美国的PAF最低（PUD为35% [24%-47%]，消化不良为3% [2%-13%]，胃淋巴瘤为17% [5%-31%]），而韩国最高（PUD为63% [50%-73%]，消化不良为9% [2%-15%]，胃淋巴瘤为39% [14%-58%]）。然而，即使在美国，PUD（13.4万例 [9.3万-17.7万]）和消化不良（86万例 [19.6万-150万]）的可预防病例数依然相当可观。

结论：在关于H. pylori筛查与治疗的研究中，若忽略PUD和消化不良作为结局指标，可能会严重低估其带来的益处。因此，将这些疾病与胃癌一并纳入成本效益和政策分析，有望改进对H. pylori筛查与治疗项目的评估。实际获益的程度取决于H. pylori在生命早期多大程度上触发了不可逆的疾病进程。

### 第二部分 AI 大师评价

本研究的核心价值在于，它系统性地量化了幽门螺杆菌（H. pylori）在胃癌之外所造成的巨大疾病负担，特别是消化性溃疡和消化不良。通过计算人群归因分数，研究明确揭示了全球范围内根除H. pylori对于预防这些常见病的巨大潜力，即使在低流行率国家亦是如此。这项研究的创新性在于其拓宽了传统视角，有力地论证了在评估H. pylori筛查与治疗策略的成本效益时，必须将这些非癌症结局纳入考量，从而为优化全球公共卫生政策提供了强有力的数据支持。

---

## 5. 肝病病因的变迁支持降低甲胎蛋白阈值用于肝细胞癌筛查

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236449](https://pubmed.ncbi.nlm.nih.gov/41236449)
**期刊：** Gastroenterology
**PMID：** 41236449
**DOI：** 10.1053/j.gastro.2025.08.021

### 第一部分 原文与翻译

**英文原标题：** Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.

**英文摘要原文：**
BACKGROUND & AIMS: Serum alpha-fetoprotein (AFP) is a key component of hepatocellular carcinoma (HCC) screening, but its test characteristics are uncertain as alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) rates increase.

METHODS: We evaluated AFP trends at HCC diagnosis and estimated its test performance for HCC screening in cirrhosis using Veterans Health Administration (VHA) and United Network for Organ Sharing data.

RESULTS: Among the 40,399 VHA patients diagnosed with HCC between 2001 and 2021, median AFP at HCC diagnosis declined over time and was highest in active-hepatitis C (HCV) (32.7 vs cured-HCV 8.3, ALD 9.0, MASLD 7.7 ng/mL). Among the 28,170 VHA patients with cirrhosis receiving care in 2019 (9.6% active-HCV, 43% cured-HCV, 24% ALD, 14% MASLD), 1,029 developed HCC in 2019. At AFP thresholds ≥20 and ≥10 ng/mL, the overall sensitivity/specificity for HCC screening was 31.7%/98.5% and 41.9%/94.1%, respectively. Lowering the AFP threshold to ≥10 ng/mL increased sensitivity with minimal reductions in specificity across all liver disease etiologies: active-HCV (sensitivity/specificity: 43.7% to 60.7%/92.6% to 83.0%), cured-HCV (32.5% to 41.5%/99.0% to 94.7%), ALD (22.8% to 32.3%/99.2% to 95.1%), and MASLD (21.7% to 29.9%/99.4% to 96.7%). Analysis of United Network for Organ Sharing (26,213 patients with HCC) resulted in similar increases in test sensitivity as the AFP threshold declined from ≥20 to ≥10 ng/mL (overall: 31.8% to 48.7%; active-HCV: 36.7% to 58.6%, cured-HCV: 21.4% to 36.4%, MASLD: 19.1% to 33.4%, and ALD: 15.9% to 27.1%).

CONCLUSIONS: For HCC screening in MASLD, ALD, and cured-HCV cirrhosis, reducing the AFP threshold to ≥10 ng/mL would substantially increase sensitivity while maintaining very high specificity.

**中文摘要译文：**
背景与目的：血清甲胎蛋白（AFP）是肝细胞癌（HCC）筛查的关键组成部分，但随着酒精相关性肝病（ALD）和代谢功能障碍相关脂肪性肝病（MASLD）发病率的增加，其检测特性变得不确定。

方法：我们利用退伍军人健康管理局（VHA）和器官共享联合网络的数据，评估了HCC诊断时的AFP趋势，并估算了其在肝硬化患者中用于HCC筛查的检测性能。

结果：在2001年至2021年间确诊为HCC的40,399名VHA患者中，HCC诊断时的中位AFP水平随时间推移而下降，并且在活动性丙型肝炎（HCV）患者中最高（32.7 ng/mL），相比之下，治愈的HCV患者为8.3 ng/mL，ALD患者为9.0 ng/mL，MASLD患者为7.7 ng/mL。在2019年接受治疗的28,170名VHA肝硬化患者中（其中9.6%为活动性HCV，43%为已治愈HCV，24%为ALD，14%为MASLD），有1,029人在2019年发展为HCC。当AFP阈值设为≥20 ng/mL和≥10 ng/mL时，用于HCC筛查的总体灵敏度/特异性分别为31.7%/98.5%和41.9%/94.1%。将AFP阈值降至≥10 ng/mL，在所有肝病病因中均提高了灵敏度，而特异性仅有轻微下降：活动性HCV（灵敏度/特异性：从43.7%升至60.7%/从92.6%降至83.0%），已治愈HCV（从32.5%升至41.5%/从99.0%降至94.7%），ALD（从22.8%升至32.3%/从99.2%降至95.1%），以及MASLD（从21.7%升至29.9%/从99.4%降至96.7%）。对器官共享联合网络数据（26,213名HCC患者）的分析也得出了相似的结果，当AFP阈值从≥20 ng/mL降至≥10 ng/mL时，检测灵敏度同样增加（总体：从31.8%升至48.7%；活动性HCV：从36.7%升至58.6%，已治愈HCV：从21.4%升至36.4%，MASLD：从19.1%升至33.4%，ALD：从15.9%升至27.1%）。

结论：对于MASLD、ALD和HCV治愈后的肝硬化患者进行HCC筛查，将AFP阈值降至≥10 ng/mL会显著提高灵敏度，同时保持非常高的特异性。

### 第二部分 AI 大师评价

本研究旨在应对肝病病因谱变化（尤其是MASLD和ALD增多）的背景，通过分析两个大型真实世界数据库（VHA和UNOS），重新评估血清甲胎蛋白（AFP）用于肝细胞癌（HCC）筛查的最佳阈值。研究关键发现，将AFP筛查阈值从传统的≥20 ng/mL下调至≥10 ng/mL，能显著提高对非病毒性肝病及HCV治愈后患者的筛查灵敏度，而特异性仅轻微下降。该研究基于大规模数据，为修订HCC筛查指南提供了强有力的循证医学证据，对于提高非病毒性肝癌的早期诊断率具有重要的临床指导价值。

---

## 6. 胃肠胰神经内分泌肿瘤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236448](https://pubmed.ncbi.nlm.nih.gov/41236448)
**期刊：** Gastroenterology
**PMID：** 41236448
**DOI：** 10.1053/j.gastro.2025.07.004

### 第一部分 原文与翻译

**英文原标题：** Gastroenteropancreatic Neuroendocrine Tumors.

**英文摘要原文：**
Neuroendocrine tumors (NETs) represent a heterogeneous group of neoplasms with diverse biological and clinical behavior, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common subtype. This review provides an overview of GEP-NETs, with a focus on incidence trends, pathologic classification, diagnostic strategies, therapeutic advances, and the role of endoscopy in diagnosis and management of GEP-NETs. Incidence rates of GEP-NETs have significantly increased over recent decades, largely due to improved diagnostic modalities and increased use of endoscopy, although environmental factors may be at play as well. Pathologic grading and classification, based on the 2022 World Health Organization criteria, remain essential in defining prognosis and therapeutic options, and advanced imaging modalities like somatostatin receptor positron emission tomography scans enable precise localization and staging. Therapeutic approaches vary by tumor grade, stage, and localization, from an increasing role for endoscopic management of indolent tumors to surgical resection for certain higher-risk subtypes and for resectable metastatic disease. Novel treatments, including somatostatin analogs, radioligand therapy, mammalian target of rapamycin inhibitors, and antiangiogenic agents, have shown significant efficacy in advanced and metastatic disease. Future research is needed to identify molecular markers to refine diagnostic accuracy and personalize treatment strategies, thereby improving long-term outcomes for GEP-NET patients. Additionally, research is needed to better define GEP-NET subtypes that are appropriate for endoscopic therapy as well as to understand long-term outcomes after endoscopic resection. Given the important role that endoscopy has in the diagnosis and management of GEP-NETs, increased recognition of and knowledge about these tumors is critical for the gastroenterology community.

**中文摘要译文：**
神经内分泌肿瘤（NETs）是一组具有不同生物学和临床行为的异质性肿瘤，其中胃肠胰神经内分泌肿瘤（GEP-NETs）是最常见的亚型。本篇综述概述了GEP-NETs，重点关注其发病率趋势、病理学分类、诊断策略、治疗进展以及内镜在GEP-NETs诊断和管理中的作用。近几十年来，GEP-NETs的发病率显著增加，这主要归因于诊断方式的改进和内镜使用的增多，尽管环境因素也可能在其中发挥作用。基于2022年世界卫生组织标准的病理学分级和分类，在确定预后和治疗方案方面仍然至关重要，而生长抑素受体正电子发射断层扫描等先进的影像学方法能够实现精确定位和分期。治疗方法因肿瘤分级、分期和部位而异，从内镜在惰性肿瘤管理中日益重要的作用，到对某些高风险亚型和可切除的转移性疾病进行手术切除。包括生长抑素类似物、放射性配体疗法、哺乳动物雷帕霉素靶蛋白抑制剂和抗血管生成药物在内的新型疗法，已在晚期和转移性疾病中显示出显著疗效。未来的研究需要识别分子标志物，以提高诊断准确性并制定个性化治疗策略，从而改善GEP-NET患者的长期预后。此外，还需要进一步研究以更好地界定适合内镜治疗的GEP-NET亚型，并了解内镜切除术后的长期结局。鉴于内镜在GEP-NETs诊断和管理中的重要作用，提高胃肠病学界对这些肿瘤的认识和了解至关重要。

### 第二部分 AI 大师评价

这篇综述全面概述了胃肠胰神经内分泌肿瘤（GEP-NETs）的最新进展。文章系统性地总结了该疾病在发病趋势、病理分类、诊断策略及治疗方法等方面的核心知识，并特别强调了内镜在诊断与治疗中日益增长的重要性。该文的价值在于为胃肠病学领域的临床医生和研究者提供了一个清晰、前沿的知识框架，指出了未来在分子标志物和内镜治疗长期效果等方面的研究方向，具有重要的临床指导意义和科研参考价值。

---

## 7. 饿死肿瘤，点燃免疫之火：短期饥饿通过重编程肝细胞癌中的巨噬细胞增强免疫检查点阻断疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236348](https://pubmed.ncbi.nlm.nih.gov/41236348)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41236348
**DOI：** 10.1097/HEP.0000000000001550

### 第一部分 原文与翻译

**英文原标题：** Starve the tumor, fuel the immune fire: Short-term starvation enhances checkpoint blockade via macrophage reprogramming in HCC.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究基于其标题判断，旨在探索短期饥饿这一代谢干预手段如何影响肝细胞癌（HCC）的免疫检查点阻断治疗。研究的核心发现揭示了短期饥饿能够通过重编程肿瘤相关巨噬细胞，进而增强免疫治疗的效果，这为“饿死肿瘤，激活免疫”的协同策略提供了直接证据。该研究巧妙地将代谢调控与肿瘤免疫连接起来，具有高度的创新性，为改善HCC免疫治疗效果提供了极具前景且成本低廉的新策略。然而，由于缺乏摘要信息，其具体的分子机制和临床转化潜力尚需阅读全文方能深入评估。

---

## 8. Prickle4驱动IDH突变型胶质瘤的微环境重塑及对PARP抑制的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41236163](https://pubmed.ncbi.nlm.nih.gov/41236163)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41236163
**DOI：** 10.1002/advs.202503866

### 第一部分 原文与翻译

**英文原标题：** Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH-Mutant Glioma.

**英文摘要原文：**
Mutations in isocitrate dehydrogenase (IDH) genes sensitize gliomas to PARP inhibition (PARPi) by inducing epigenetic reprogramming of DNA damage repair circuits. However, tumors treated with PARPi eventually relapse despite initial responsiveness. In this study, it is demonstrated that the anti-angiogenic agent lenvatinib synergizes effectively with PARPi, resulting in substantial tumor regression and significantly extended survival. Genomic analysis of tumors reveals that PARPi induces widespread transcriptomic changes that are predominantly pro-inflammatory, thereby promoting tumor angiogenesis. Prickle4, a planar cell polarity protein, is identified as a critical mediator of PARPi-induced neovascularization. Targeting Prickle4 effectively overcomes PARPi resistance in these tumors. Collectively, these findings identified the Prickle4-mediated microenvironmental remodeling as the key resistance mechanism to PARPi, and support the therapeutic promise of multimodal therapy combining PARPi with anti-angiogenic agents for glioma treatment.

**中文摘要译文：**
异柠檬酸脱氢酶（IDH）基因突变通过诱导DNA损伤修复环路的表观遗传重编程，使胶质瘤对PARP抑制（PARPi）敏感。然而，尽管初期反应良好，接受PARPi治疗的肿瘤最终仍会复发。本研究证明，抗血管生成药物仑伐替尼与PARPi能有效协同，导致肿瘤显著消退并显著延长生存期。对肿瘤的基因组学分析揭示，PARPi会诱导广泛的转录组学变化，这些变化主要是促炎性的，从而促进了肿瘤血管生成。Prickle4，一种平面细胞极性蛋白，被确定为PARPi诱导的新生血管形成的关键介质。靶向Prickle4能有效克服这些肿瘤中的PARPi耐药性。总而言之，这些发现将Prickle4介导的微环境重塑确定为对PARPi产生耐药性的关键机制，并支持将PARPi与抗血管生成药物相结合的多模式疗法在胶质瘤治疗中的应用前景。

### 第二部分 AI 大师评价

本研究旨在揭示IDH突变型胶质瘤对PARP抑制剂（PARPi）产生耐药的潜在机制，并探索联合治疗策略。研究通过基因组学分析发现，PARPi治疗会诱导以Prickle4蛋白为关键介质的促炎性微环境重塑和肿瘤血管生成，从而导致耐药。该研究的创新之处在于阐明了Prickle4在PARPi耐药中的核心作用，并验证了联合使用PARPi与抗血管生成药物（仑伐替尼）的协同效应，为克服胶质瘤治疗耐药提供了新的靶点和极具潜力的临床治疗方案。

---

## 9. RAS/BRAF V600E 突变对错配修复缺陷/微卫星不稳定性结直肠癌肿瘤免疫微环境的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41235954](https://pubmed.ncbi.nlm.nih.gov/41235954)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41235954
**DOI：** 10.1158/1078-0432.CCR-25-2160

### 第一部分 原文与翻译

**英文原标题：** Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers.

**英文摘要原文：**
PURPOSE: Routine testing for dMMR/MSI in colorectal cancers (CRCs) is recommended for Lynch Syndrome screening, prognosis, and treatment guidance. In the metastatic setting, RASBRAF mutations guide treatment decisions. The impact of these mutations on tumor immune microenvironment (TiME) in MSI/dMMR CRC are not known.

EXPERIMENTAL DESIGN: Retrospective analysis of 448 patients with stage I-IV MSI/dMMR CRC profiled using next-generation sequencing (NGS) (Tempus xT DNA-seq of 595-648 genes at 500x coverage and Tempus xR whole-exome capture RNA-seq). MSI status was determined by assessing 44 or 239 loci using NGS. dMMR was determined using immunohistochemistry (IHC). Tumor mutational burden (TMB), tumor neoantigen burden (NTB), PD-L1, immune infiltration, and canonical immune pathways (76 gene set signatures) were analyzed.

RESULTS: The median age at diagnosis was 67 years (range 21-86), 59% female, and 70% stage III-IV. Among the 448, 100 (22%) harbored RAS mutations (RASmut), 119 (27%) a BRAFV600E mutation, and 229 (51%) were double wild-type (RASwt, BRAFwt). RASmut exhibited lower NTB (median 12 vs. 15 vs. 16, p=0.003) and PD-L1 (3.6% vs. 13% vs. 24%, p<0.001) than BRAFV600E and wild-type tumors, respectively. The RASmut TiME had lower overall inflammation and fewer infiltrating CD8+ T-cells than wild-type or BRAFV600E tumors. In contrast, BRAFV600E tumors exhibited hyperproliferative characteristics associated with broad metabolic reprogramming but similarly inflamed TiME compared to wild-type tumors.

CONCLUSIONS: Our data suggest that MSI/dMMR CRCs harboring RASmut are less immunogenic and TiME contains a lower inflammatory profile than wild-type or BRAFV600E tumors. Further analysis and validation are required to confirm these findings.

**中文摘要译文：**
目的: 建议对结直肠癌（CRC）进行错配修复缺陷（dMMR）/微卫星不稳定性（MSI）的常规检测，以用于林奇综合征筛查、预后判断和治疗指导。在转移性疾病的背景下，RAS/BRAF突变指导治疗决策。这些突变对dMMR/MSI型CRC中肿瘤免疫微环境（TiME）的影响尚不清楚。

实验设计: 对448名I-IV期dMMR/MSI型CRC患者进行回顾性分析，这些患者使用下一代测序（NGS）进行了基因谱分析（Tempus xT DNA测序，覆盖595-648个基因，覆盖度500x；以及Tempus xR全外显子组捕获RNA测序）。通过NGS评估44或239个位点来确定MSI状态。通过免疫组织化学（IHC）确定dMMR状态。分析了肿瘤突变负荷（TMB）、肿瘤新抗原负荷（NTB）、PD-L1、免疫浸润和经典免疫通路（76个基因集特征）。

结果: 诊断时的中位年龄为67岁（范围21-86岁），59%为女性，70%为III-IV期。在这448名患者中，100名（22%）携带RAS突变（RASmut），119名（27%）携带BRAFV600E突变，229名（51%）为双野生型（RASwt, BRAFwt）。与BRAFV600E突变型和野生型肿瘤相比，RASmut型肿瘤分别表现出更低的新抗原负荷（NTB）（中位数12 vs. 15 vs. 16, p=0.003）和PD-L1表达（3.6% vs. 13% vs. 24%, p<0.001）。RASmut型肿瘤的免疫微环境（TiME）总体炎症水平较低，浸润的CD8+ T细胞也比野生型或BRAFV600E突变型肿瘤少。相比之下，BRAFV600E突变型肿瘤表现出与广泛代谢重编程相关的高增殖特性，但其肿瘤免疫微环境的炎症程度与野生型肿瘤相似。

结论: 我们的数据表明，携带RAS突变的dMMR/MSI型CRC的免疫原性较低，其肿瘤免疫微环境的炎症特征也弱于野生型或BRAFV600E突变型肿瘤。需要进一步的分析和验证来证实这些发现。

### 第二部分 AI 大师评价

本研究通过一项大规模回顾性分析，创新性地探究了在dMMR/MSI型结直肠癌这一特殊亚型中，RAS/BRAF V600E突变状态如何影响肿瘤免疫微环境。研究关键发现，携带RAS突变的肿瘤呈现出免疫原性较低的“冷”肿瘤特征，这与传统上认为dMMR/MSI肿瘤免疫原性高的观念形成对比。这一发现对于临床实践具有重要价值，提示RAS突变状态可作为dMMR/MSI结直肠癌患者免疫治疗疗效的潜在预测生物标志物，有助于更精准地筛选优势人群。尽管研究结论尚需前瞻性研究证实，但它为理解肿瘤内在基因型与免疫微环境的复杂互作提供了新视角。

---

## 10. HER2阳性作为晚期胆道癌的预后生物标志物和治疗靶点：一项多中心分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41235921](https://pubmed.ncbi.nlm.nih.gov/41235921)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41235921
**DOI：** 10.1158/1078-0432.CCR-25-2153

### 第一部分 原文与翻译

**英文原标题：** HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional Analysis.

**英文摘要原文：**
PURPOSE: This study aimed to evaluate the prognostic relevance of HER2-positivity and the clinical impact of anti-HER2 therapy in the management of advanced biliary tract cancers (BTCs), using integrated multi-institutional data.

EXPERIMENTAL DESIGN: This retrospective analysis included 388 patients with advanced BTCs and known HER2 status from Yonsei Cancer Center and MD Anderson Cancer Center between 2009 and 2023. HER2-positivity was defined as HER2 immunohistochemistry (IHC) 3+, IHC 2+ with in situ hybridization (ISH)-positivity, or ERBB2 amplification by next-generation sequencing (NGS). Clinical outcomes, including survival, and genomic profiling with curated oncogenic pathway enrichment were analyzed.

RESULTS: HER2-positivity was observed in 25.2% of the epidemiology analysis cohort (n=309). In the survival analysis (n=310), HER2-positive BTCs were associated with shorter overall survival (OS) (13.7 vs. 17.1 months; HR, 1.25; 95% CI, 0.97-1.60) and significantly shorter first-line progression-free survival (5.1 vs. 7.4 months; HR, 1.91; 95% CI, 1.46-2.48) than HER2-negative BTCs. Anti-HER2 therapy significantly improved OS among HER2-positive patients (18.2 vs. 8.1 months; HR, 0.39; 95% CI, 0.21-0.62). Genomic analysis showed the strongest enrichment of angiogenesis pathway alterations in HER2-positive patients, while KRAS mutations were predominant in HER2-negative BTCs.

CONCLUSION: HER2 is a clinically meaningful biomarker with prognostic and predictive relevance in advanced BTCs. Anti-HER2 therapy significantly improves survival in HER2-positive patients. These findings support routine HER2 testing, standardization of HER2 diagnostic criteria, and further prospective evaluation of HER2-targeted strategies for BTCs.

**中文摘要译文：**
目的：本研究旨在利用综合性多中心数据，评估HER2阳性在晚期胆道癌（BTCs）管理中的预后相关性以及抗HER2治疗的临床影响。

实验设计：这项回顾性分析纳入了2009年至2023年间来自延世癌症中心和MD安德森癌症中心的388名HER2状态已知的晚期BTCs患者。HER2阳性定义为HER2免疫组织化学（IHC）3+、IHC 2+伴原位杂交（ISH）阳性，或通过二代测序（NGS）检测到ERBB2扩增。研究分析了包括生存期在内的临床结局，以及经过筛选的致癌通路富集的基因组图谱。

结果：在流行病学分析队列（n=309）中，25.2%的患者观察到HER2阳性。在生存分析（n=310）中，与HER2阴性BTCs相比，HER2阳性BTCs的总生存期（OS）更短（13.7个月 vs. 17.1个月；HR, 1.25; 95% CI, 0.97-1.60），且一线无进展生存期显著缩短（5.1个月 vs. 7.4个月；HR, 1.91; 95% CI, 1.46-2.48）。在HER2阳性患者中，抗HER2治疗显著改善了总生存期（18.2个月 vs. 8.1个月；HR, 0.39; 95% CI, 0.21-0.62）。基因组分析显示，HER2阳性患者中血管生成通路的改变最为富集，而KRAS突变在HER2阴性BTCs中占主导地位。

结论：在晚期BTCs中，HER2是一个具有预后和预测相关性的临床意义重大的生物标志物。抗HER2治疗能显著改善HER2阳性患者的生存状况。这些发现支持对BTCs进行常规HER2检测、统一HER2诊断标准，并进一步开展HER2靶向策略的前瞻性评估。

### 第二部分 AI 大师评价

本研究通过一项大规模多中心回顾性分析，系统评估了HER2阳性在晚期胆道癌（BTC）中的预后价值及抗HER2治疗的临床疗效。研究明确指出，HER2阳性是晚期BTC的不良预后因素，但同时也证实了抗HER2治疗能为该患者亚群带来显著的生存获益。此项工作不仅为临床常规开展BTC的HER2检测提供了坚实证据，也揭示了HER2阳性与阴性肿瘤在基因层面的差异，为未来精准治疗策略的开发和优化指明了方向。

---

## 11. 艾拉司群治疗ER阳性、HER2阴性、ESR1突变型转移性乳腺癌的真实世界结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41235919](https://pubmed.ncbi.nlm.nih.gov/41235919)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41235919
**DOI：** 10.1158/1078-0432.CCR-25-3040

### 第一部分 原文与翻译

**英文原标题：** Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.

**英文摘要原文：**
PURPOSE: The EMERALD trial led to approval of elacestrant for ER-positive, HER2-negative ESR1-mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET). Subgroup analyses provided evidence suggesting elacestrant enables ET sequencing in the second line before other targeted combinations, which could delay chemotherapy-based regimens.

EXPERIMENTAL DESIGN: This study used claims data from Komodo Research Dataset linked with Foundation Medicine Inc. clinical-genomic data from patients with ER+/HER2- mBC harboring an ESR1 mutation treated with elacestrant. The primary outcome measure was time-to-next-treatment (TTNT).

RESULTS: Among 306 patients, 93.8% had prior ET±CDK4/6i ≥12 months, 50.0% prior chemotherapy, and 72.2% prior fulvestrant. Median TTNT was 8.2 months (95% CI, 6.3-13.0) in patients with 1-2 prior lines and 7.5 months (95% CI, 7.1-9.9) in those with ≥3 prior lines of ET. In patients with coexisting ESR1 and PI3K-pathway mutated tumors, median TTNT was 6.3 months (95% CI, 4.8-7.9). Median TTNT was 7.9 months (95% CI, 7.1-9.8) in all patients and was also sustained in patients with no prior fulvestrant (12.9 months [95% CI, 7.2-NR]), no prior chemotherapy (8.4 months [95% CI, 7.1-13.3]), visceral metastasis (7.9 months [95% CI, 7.0-9.9]), and liver metastases (7.2 months [95% CI, 6.3-9.0]).

CONCLUSIONS: Elacestrant demonstrated durable benefit in real-world clinical practice, particularly in earlier lines and in patients with prolonged prior ET exposure. Despite coexisting ESR1 and PI3K-pathway mutations, TTNT remained clinically meaningful, reinforcing the role of elacestrant in personalized ET sequencing strategies prior to chemotherapy, antibody-drug conjugates, or targeted combinations.

**中文摘要译文：**
目的：EMERALD试验促使艾拉司群获批用于治疗既往接受至少一线内分泌治疗（ET）后疾病进展的ER阳性、HER2阴性、ESR1突变的晚期或转移性乳腺癌（mBC）。亚组分析提供的证据表明，在采用其他靶向联合治疗前，于二线使用艾拉司群进行内分泌序贯治疗是可行的，这可能推迟基于化疗的方案。

试验设计：本研究使用了来自Komodo研究数据集的理赔数据，并将其与来自Foundation Medicine公司的临床基因组数据相关联，这些数据源于接受艾拉司群治疗的、携带ESR1突变的ER+/HER2- mBC患者。主要结局指标为至下一次治疗时间（TTNT）。

结果：在306名患者中，93.8%的患者既往接受ET±CDK4/6i治疗≥12个月，50.0%的患者既往接受过化疗，72.2%的患者既往使用过氟维司群。在既往接受过1-2线ET治疗的患者中，中位TTNT为8.2个月（95% CI, 6.3-13.0），而在既往接受过≥3线ET治疗的患者中，中位TTNT为7.5个月（95% CI, 7.1-9.9）。在同时存在ESR1和PI3K通路突变的肿瘤患者中，中位TTNT为6.3个月（95% CI, 4.8-7.9）。所有患者的中位TTNT为7.9个月（95% CI, 7.1-9.8），并且在既往未使用过氟维司群（12.9个月 [95% CI, 7.2-NR]）、未接受过化疗（8.4个月 [95% CI, 7.1-13.3]）、存在内脏转移（7.9个月 [95% CI, 7.0-9.9]）以及肝转移（7.2个月 [95% CI, 6.3-9.0]）的患者中，疗效同样持久。

结论：艾拉司群在真实世界临床实践中显示出持久的获益，尤其是在早期治疗线数以及既往长期接受ET暴露的患者中。尽管同时存在ESR1和PI3K通路突变，TTNT仍具有临床意义，这加强了艾拉司群在化疗、抗体药物偶联物或靶向联合治疗之前，作为个性化ET序贯策略的作用。

### 第二部分 AI 大师评价

本研究利用大规模真实世界数据库，旨在评估新型口服SERD药物艾拉司群在ER+/HER2-、ESR1突变转移性乳腺癌患者中的实际临床疗效。研究核心发现，艾拉司群展现了持久的临床获益，其中位“至下一次治疗时间”（TTNT）具有临床意义，尤其是在治疗线数靠前和既往内分泌治疗暴露时间较长的患者中。这项研究为关键的EMERALD临床试验提供了重要的真实世界证据补充，有力支持了艾拉司群作为化疗前的有效内分泌序贯治疗选择，对指导临床个体化决策具有重要价值。

---

## 12. 肿瘤源性白细胞介素-35通过激活胰腺星状细胞促进胰腺癌肿瘤微环境的纤维化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41235536](https://pubmed.ncbi.nlm.nih.gov/41235536)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41235536
**DOI：** 10.1002/advs.202509074

### 第一部分 原文与翻译

**英文原标题：** Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells.

**英文摘要原文：**
Severe fibrosis, predominantly driven by the activation of pancreatic stellate cells (PSCs), plays a crucial role in the poor prognosis associated with pancreatic ductal adenocarcinoma (PDAC). Understanding the intricate interplay between tumor cells and their microenvironment is essential for deciphering the regulatory mechanisms underlying PSC activation. This study sheds light on the critical role of tumor-derived interleukin-35 (IL-35) in modulating PSC activation, thereby unveiling a promising therapeutic target for mitigating PDAC progression. This study demonstrates that IL-35, secreted by PDAC cells, serves as a key mediator of bidirectional communication between PDAC cells and PSCs, exacerbating fibrosis. Specifically, IL-35 upregulates the expression of IGFBP2 and Tsp-1 in PDAC cells, which subsequently activates PSCs through the IGF-1R/phosphoinositide 3-kinase/Akt and transforming growth factor beta signaling pathways, respectively. This sequential activation fosters an environment conducive to tumor cell proliferation and migration, ultimately driving accelerated tumor growth. Collectively, these findings indicate that IL-35 is a promising therapeutic target whose blockade not only suppresses PSC activation and stromal fibrosis, but also enhances the efficacy of standard chemotherapies (gemcitabine and gemcitabine/nab-paclitaxel). This provides a strong rationale for its clinical development as a combinatorial strategy in PDAC treatment.

**中文摘要译文：**
严重的纤维化在胰腺导管腺癌（PDAC）的不良预后中起着关键作用，而这主要由胰腺星状细胞（PSCs）的激活所驱动。理解肿瘤细胞与其微环境之间复杂的相互作用对于阐明PSC激活的调控机制至关重要。本研究揭示了肿瘤源性白细胞介素-35（IL-35）在调节PSC激活中的关键作用，从而发现了一个减轻PDAC进展的潜在治疗靶点。本研究表明，由PDAC细胞分泌的IL-35是PDAC细胞与PSC之间双向通讯的关键介质，并加剧了纤维化。具体而言，IL-35上调PDAC细胞中IGFBP2和Tsp-1的表达，后者分别通过IGF-1R/磷脂酰肌醇3-激酶/Akt和转化生长因子-β信号通路激活PSC。这种序贯激活营造了一个有利于肿瘤细胞增殖和迁移的环境，最终驱动肿瘤加速生长。总的来说，这些发现表明IL-35是一个有前景的治疗靶点，阻断它不仅能抑制PSC的激活和基质纤维化，还能增强标准化疗（吉西他滨和吉西他滨/白蛋白紫杉醇）的疗效。这为其作为PDAC治疗中联合策略的临床开发提供了有力的理论依据。

### 第二部分 AI 大师评价

本研究旨在阐明肿瘤源性白细胞介素-35（IL-35）在胰腺癌微环境中驱动纤维化的具体机制。研究发现，癌细胞分泌的IL-35通过上调自身的IGFBP2和Tsp-1，间接激活胰腺星状细胞，从而加剧纤维化并促进肿瘤生长。这一发现揭示了肿瘤细胞与基质细胞间一种新颖的序贯激活通讯模式，创新性地指出了IL-35是克服胰腺癌基质屏障、增强化疗敏感性的关键治疗靶点，具有重要的临床转化潜力。

---

## 13. 贝伐珠单抗联合分次立体定向放疗治疗非小细胞肺癌广泛性脑转移的疗效与安全性：一项前瞻性II期研究 (GASTO-1053)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41235462](https://pubmed.ncbi.nlm.nih.gov/41235462)
**期刊：** Cancer communications (London, England)
**PMID：** 41235462
**DOI：** 10.1002/cac2.70078

### 第一部分 原文与翻译

**英文原标题：** Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053).

**英文摘要原文：**
BACKGROUND: The prognosis for non-small cell lung cancer (NSCLC) patients with extensive brain metastases (BMs) treated with radiotherapy alone remains poor. Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab (Bev) with fractionated stereotactic radiotherapy (FSRT) in managing extensive BMs in NSCLC patients who had stable extracranial disease.

METHODS: Patients with extensive BMs from NSCLC, deemed unsuitable for stereotactic radiosurgery, were prospectively enrolled following multidisciplinary tumor board evaluation. Patients received FSRT (40 Gy in 10 fractions or 30 Gy in 5 fractions) in combination with Bev (7.5 mg/kg on day 1 prior to FSRT and on day 21 post-FSRT). The primary endpoint was intracranial progression-free survival (IPFS). Secondary endpoints included overall survival, progression-free survival, quality of life (QOL), and toxicities. For comparison, NSCLC patients with extensive BMs treated with whole-brain radiotherapy (WBRT) plus FSRT or FSRT alone were matched 1:1 with the study group (Bev + FSRT) using the propensity score matching.

RESULTS: One hundred and six patients were included in the Bev + FSRT group, with a median follow-up duration of 35.8 months. The median IPFS was 18.3 months (95% confidence interval, 15.2-23.3 months). The Bev + FSRT group showed a significant improvement in IPFS compared to both the WBRT + FSRT group (9.6 months, P < 0.001) and the FSRT alone group (8.9 months, P < 0.001). Treatment was well tolerated, with grade 1 radiation necrosis in 1 patient. Bev + FSRT treatment significantly reduced tumor volume (P < 0.001), peritumoral edema volume (P = 0.004), and vascular leakage (P < 0.001). Furthermore, QOL was significantly improved after Bev + FSRT treatment, particularly in patients with symptomatic extensive BMs.

CONCLUSION: These findings support the combination of Bev and FSRT as a safe and effective treatment strategy for extensive BMs in NSCLC patients, offering improved intracranial disease control and symptom relief while avoiding the neurotoxicity associated with WBRT. A randomized trial is warranted to validate the findings of the current study.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT04345146. Registration date: 2020-02-22.

**中文摘要译文：**
背景：对于仅接受放疗的广泛性脑转移（BMs）的非小细胞肺癌（NSCLC）患者，其预后仍然很差。基于放疗与血管生成抑制剂的协同潜力，我们启动了这项II期研究，旨在评估贝伐珠单抗（Bev）联合分次立体定向放疗（FSRT）在治疗颅外疾病稳定的NSCLC患者广泛性脑转移中的疗效与安全性。

方法：经多学科肿瘤委员会评估，不适合接受立体定向放射外科治疗的NSCLC广泛性脑转移患者被前瞻性地纳入本研究。患者接受FSRT（40 Gy/10次或30 Gy/5次）联合Bev（FSRT前第1天和FSRT后第21天，剂量为7.5 mg/kg）治疗。主要终点是颅内无进展生存期（IPFS）。次要终点包括总生存期、无进展生存期、生活质量（QOL）和毒性反应。为了进行比较，采用倾向性评分匹配法，将接受全脑放疗（WBRT）联合FSRT或单独接受FSRT治疗的NSCLC广泛性脑转移患者与研究组（Bev + FSRT）进行1:1匹配。

结果：Bev + FSRT组共纳入106名患者，中位随访时间为35.8个月。中位IPFS为18.3个月（95%置信区间，15.2-23.3个月）。与WBRT + FSRT组（9.6个月，P < 0.001）和单独FSRT组（8.9个月，P < 0.001）相比，Bev + FSRT组的IPFS有显著改善。治疗耐受性良好，仅1名患者出现1级放射性坏死。Bev + FSRT治疗显著减小了肿瘤体积（P < 0.001）、瘤周水肿体积（P = 0.004）和血管渗漏（P < 0.001）。此外，Bev + FSRT治疗后患者的生活质量得到显著改善，尤其是在有症状的广泛性脑转移患者中。

结论：这些研究结果支持将Bev与FSRT联合应用作为治疗NSCLC广泛性脑转移的一种安全有效的策略，它能在改善颅内疾病控制和缓解症状的同时，避免与WBRT相关的神经毒性。有必要开展一项随机试验来验证当前研究的发现。

试验注册：ClinicalTrials.gov, NCT04345146。注册日期：2020-02-22。

### 第二部分 AI 大师评价

本研究是一项前瞻性II期临床试验，旨在探索贝伐珠单抗联合分次立体定向放疗（FSRT）治疗非小细胞肺癌广泛性脑转移的安全性和有效性。其关键发现是，该联合方案显著延长了患者的颅内无进展生存期，并改善了生活质量，且耐受性良好。这项研究的创新价值在于，为不适合传统全脑放疗（WBRT）的患者提供了一种极具潜力的新治疗选择，既能有效控制颅内病灶，又能避免WBRT带来的神经毒性，但其结论仍需未来更大规模的随机对照试验来进一步验证。

---

## 14. 勘误：经骨髓瘤修饰的脂肪细胞表现出代谢功能障碍和衰老相关的分泌表型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41234128](https://pubmed.ncbi.nlm.nih.gov/41234128)
**期刊：** Cancer research
**PMID：** 41234128
**DOI：** 10.1158/0008-5472.CAN-25-3720

### 第一部分 原文与翻译

**英文原标题：** Correction: Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

此为一篇勘误声明，无摘要信息。从标题推断，原始研究的核心目的在于探讨多发性骨髓瘤细胞如何影响脂肪细胞的功能。该研究可能发现，受骨髓瘤影响的脂肪细胞会发生代谢紊乱，并呈现出一种与细胞衰老相关的特殊分泌模式（SASP），这可能促进了肿瘤微环境的形成和疾病进展。这项研究的价值在于揭示了脂肪细胞在骨髓瘤发病机制中的新角色，为开发靶向肿瘤微环境的治疗策略提供了潜在新思路。然而，由于缺乏具体摘要，无法评估其详细方法和发现的可靠性。

---

## 15. 编者按：在一条促进胰腺癌生长并抑制顺铂诱导的细胞凋亡的信号通路中，硫氧还蛋白位于Smad7的下游

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41234127](https://pubmed.ncbi.nlm.nih.gov/41234127)
**期刊：** Cancer research
**PMID：** 41234127
**DOI：** 10.1158/0008-5472.CAN-25-4286

### 第一部分 原文与翻译

**英文原标题：** Editor's Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献标题揭示了一项关于胰腺癌分子机制的研究，其核心目的在于阐明Smad7与硫氧还蛋白（Thioredoxin）在调控肿瘤细胞行为中的上下游关系。根据标题，该研究的关键发现是，Smad7通过调控其下游的硫氧还蛋白，形成一条促进胰腺癌细胞生长并抑制顺铂诱导的细胞凋亡的信号通路。然而，需要特别指出的是，本文献为一篇“编者按”且无摘要，这通常意味着原文可能存在重大问题或已被撤稿，因此其标题中所述结论的可靠性存疑，读者在引用或解读时应极其谨慎。

---

## 16. 白质在胶质母细胞瘤中的双重对立功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41234043](https://pubmed.ncbi.nlm.nih.gov/41234043)
**期刊：** Neuro-oncology
**PMID：** 41234043
**DOI：** 10.1093/neuonc/noaf266

### 第一部分 原文与翻译

**英文原标题：** Opposing Functions of White Matter in Glioblastoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

由于本文献无摘要，仅从标题推断，本研究可能深入探讨了白质在胶质母细胞瘤（GBM）发展进程中的复杂且相互对立的双重角色。它可能揭示了白质一方面作为肿瘤细胞侵袭和播散的“高速公路”，另一方面其独特的微环境也可能存在抑制肿瘤生长或影响治疗反应的潜在机制。该研究视角新颖，对于理解GBM的侵袭行为和开发靶向肿瘤微环境的新疗法具有重要科研价值，但具体的研究方法和关键发现需查阅全文方能知晓。

---

## 17. 将癫痫控制作为一项重要终点。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41234037](https://pubmed.ncbi.nlm.nih.gov/41234037)
**期刊：** Neuro-oncology
**PMID：** 41234037
**DOI：** 10.1093/neuonc/noaf268

### 第一部分 原文与翻译

**英文原标题：** "TREAT"ing Seizures as an Important Endpoint.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文献可能是一篇社论或观点性文章，旨在强调在神经肿瘤学研究中将癫痫控制作为一项重要临床终点指标的必要性。作者很可能论证了，除了传统的生存期和肿瘤进展等指标外，关注癫痫这一直接影响患者生活质量的症状，能更全面地评估治疗的真实临床获益。此观点推动了以患者为中心的研究设计理念，对于优化未来神经肿瘤领域的临床试验方案、评价新疗法具有重要的指导价值。

---

## 18. 酰胺质子转移加权（APTw）CEST MRI在临床常规中用于IDH野生型胶质母细胞瘤假性进展的单时间点诊断

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233976](https://pubmed.ncbi.nlm.nih.gov/41233976)
**期刊：** Neuro-oncology
**PMID：** 41233976
**DOI：** 10.1093/neuonc/noaf261

### 第一部分 原文与翻译

**英文原标题：** Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.

**英文摘要原文：**
BACKGROUND: Differentiating progressive disease (PD) from treatment-related effects (TRE) in glioblastoma remains challenging, particularly at single time point evaluations. TRE can occur at any disease stage, and its underlying biology is poorly understood. This study evaluates the clinical feasibility and diagnostic performance of amide proton transfer-weighted (APTw) MRI in this challenge.

METHODS: Following the integration of APTw MRI into the routine clinical workflow for brain tumor imaging, we screened a total of 870 scans from 626 patients. APTw signal (voxel-based measurement) was automatically quantified in gadolinium-enhanced T1w and FLAIR regions of interest using a deep learning-based approach for 3D tumor segmentations. PD and TRE were compared using unpaired t-tests, and diagnostic accuracy was assessed via ROC- and logistic regression analysis.

RESULTS: Among 256 MRI scans of 143 patients with glioblastoma, 65 scans showed PD (n = 42) or TRE (n = 23). The median APTw signal was higher in PD (2.23%) vs TRE (1.76%; p = 0.001). ROC analysis showed an area under the curve (AUC) of 0.82. In patients with early PD or TRE (<6 months post-radiotherapy), the AUC increased to 0.93. Anti-angiogenic therapy decreased APTw signal (p < 0.01). Combining APTw MRI with DWI and PWI improved diagnostic accuracy (AUC = 0.90).

CONCLUSIONS: APTw MRI is a non-invasive imaging tool that is feasible for clinical routine and aids in differentiation of early progression from pseudoprogression in glioblastoma. Its diagnostic accuracy decreases with application of anti-angiogenic treatment and at later follow-up time points. Highest diagnostic accuracy was found in a multimodal approach combining APTw MRI, PWI and DWI.

**中文摘要译文：**
背景：在胶质母细胞瘤中，区分疾病进展（PD）与治疗相关效应（TRE）仍然具有挑战性，尤其是在单时间点评估中。TRE可发生于任何疾病阶段，其潜在的生物学机制尚不明确。本研究旨在评估酰胺质子转移加权（APTw）MRI在应对这一挑战中的临床可行性及诊断性能。

方法：我们将APTw MRI整合到脑肿瘤成像的常规临床工作流程中后，共筛选了来自626名患者的870次扫描。我们采用基于深度学习的3D肿瘤分割方法，在钆增强T1加权像（T1w）和液体衰减反转恢复序列（FLAIR）的感兴趣区域内，对APTw信号（基于体素的测量）进行自动量化。使用非配对t检验对PD和TRE组进行比较，并通过受试者工作特征（ROC）曲线和逻辑回归分析评估诊断准确性。

结果：在143名胶质母细胞瘤患者的256次MRI扫描中，有65次扫描显示为PD（n = 42）或TRE（n = 23）。PD组的中位APTw信号（2.23%）高于TRE组（1.76%；p = 0.001）。ROC分析显示曲线下面积（AUC）为0.82。在放疗后6个月内发生早期PD或TRE的患者中，AUC增至0.93。抗血管生成治疗会降低APTw信号（p < 0.01）。将APTw MRI与弥散加权成像（DWI）和灌注加权成像（PWI）相结合，可提高诊断准确性（AUC = 0.90）。

结论：APTw MRI是一种无创的成像工具，在临床常规中具有可行性，有助于鉴别胶质母细胞瘤的早期进展与假性进展。其诊断准确性在使用抗血管生成治疗后以及在较晚的随访时间点会有所下降。在联合APTw MRI、PWI和DWI的多模态方法中，发现了最高的诊断准确性。

### 第二部分 AI 大师评价

本研究旨在评估酰胺质子转移加权（APTw）MRI在常规临床流程中单次检查即可鉴别胶质母细胞瘤真性进展与假性进展（治疗相关效应）的可行性与诊断效能。研究创新性地将APTw成像与深度学习分割技术相结合，实现了对肿瘤信号的自动化定量分析。关键发现是，APTw信号在真性进展中显著更高，尤其是在放疗后早期鉴别诊断中表现出极高的准确性（AUC=0.93），为解决这一临床诊断难题提供了重要的无创影像学依据。尽管研究指出抗血管生成治疗会影响其准确性，但它证实了APTw作为多模态成像（结合DWI、PWI）核心部分的巨大临床价值。

---

## 19. ClinMAVE：一个用于多重变异效应分析数据临床应用的精选数据库。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233957](https://pubmed.ncbi.nlm.nih.gov/41233957)
**期刊：** Nucleic acids research
**PMID：** 41233957
**DOI：** 10.1093/nar/gkaf1102

### 第一部分 原文与翻译

**英文原标题：** ClinMAVE: a curated database for clinical application of data from multiplexed assays of variant effect.

**英文摘要原文：**
The widespread use of next-generation sequencing in clinical practice has generated vast numbers of genetic variants from both inherited disorders and tumor profiling, many classified as variants of uncertain significance (VUS). These uncertain variants limit the clinical utility of genomic testing by constraining risk assessment, diagnosis, and treatment selection. Multiplexed Assays of Variant Effect (MAVEs) provide scalable, high-throughput functional data for variant characterization and are recognized by ACMG/AMP guidelines as valid evidence for clinical classification. However, existing resources lack harmonized annotations, structured evidence grading, and interoperability with clinical databases needed for application in genetic disease and somatic cancer workflows. Here, we developed ClinMAVE (https://ngdc.cncb.ac.cn/clinmave/), a curated database for clinical application of MAVE data. ClinMAVE offers functional evidence for over 2.1 million variants across 821 genes, with standardized annotations, detailed assay context, and ACMG/AMP-aligned evidence grading. Integrated with ClinVar, gnomAD, TCGA, and in silico tools, ClinMAVE bridges the gap between experimental data and clinical standards, providing a unified, clinician-ready platform for functional variant interpretation in both hereditary disease and cancer genomics.

**中文摘要译文：**
新一代测序技术在临床实践中的广泛应用，从遗传性疾病和肿瘤分析中产生了大量的基因变异，其中许多被归类为意义不明确的变异（VUS）。这些意义不明确的变异限制了基因组检测的临床效用，因为它对风险评估、诊断和治疗选择构成了制约。多重变异效应分析（MAVEs）为变异定性提供了可扩展、高通量的功能数据，并被ACMG/AMP指南认可为临床分类的有效证据。然而，现有资源缺乏在遗传病和体细胞癌工作流程中应用所需的统一注释、结构化证据分级以及与临床数据库的互操作性。为此，我们开发了ClinMAVE（https://ngdc.cncb.ac.cn/clinmave/），这是一个用于MAVE数据临床应用的精选数据库。ClinMAVE为821个基因中的超过210万个变异提供了功能性证据，并配备了标准化注释、详细的分析背景信息以及与ACMG/AMP标准对齐的证据分级。通过整合ClinVar、gnomAD、TCGA和多种计算工具，ClinMAVE弥合了实验数据与临床标准之间的鸿沟，为遗传性疾病和癌症基因组学中的功能性变异解读提供了一个统一的、面向临床的平台。

### 第二部分 AI 大师评价

本研究旨在解决下一代测序在临床应用中产生的海量“意义不明确的变异”（VUS）这一核心难题。研究团队通过开发ClinMAVE数据库，系统性地整合并审编了来自多重变异效应分析（MAVEs）的大规模功能数据。其关键创新在于，它不仅提供了超过210万个变异的功能证据，更重要的是将这些原始实验数据按照ACMG/AMP临床指南进行了标准化注释与证据分级，并与ClinVar等关键数据库互联。此举极大地提升了实验数据向临床决策转化的效率和可靠性，为遗传病和肿瘤基因组学中的变异解读提供了强有力的工具。

---

## 20. 由BCL11B耗竭驱动的直接重编程NK细胞可增强针对胰腺导管腺癌的靶向免疫疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233896](https://pubmed.ncbi.nlm.nih.gov/41233896)
**期刊：** Journal of hematology & oncology
**PMID：** 41233896
**DOI：** 10.1186/s13045-025-01730-1

### 第一部分 原文与翻译

**英文原标题：** Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma.

**英文摘要原文：**
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by desmoplastic stroma, immunosuppressive tumor microenvironment (TME), and resistance to standard therapies. Natural killer (NK) cell-based immunotherapies have shown limited efficacy due to impaired persistence, infiltration, and function in PDAC.

METHODS: We established a direct reprogramming strategy to generate cytotoxic NK cells (1 F-NKs) by targeting BCL11B, a transcription factor essential for T cell lineage commitment, using shRNA or CRISPR/Cas9 in peripheral blood mononuclear cells (PBMCs). A genome-wide CRISPR/Cas9 screen identified tumor-intrinsic modulators of NK resistance. Functional and in vivo studies assesses the efficacy of 1 F-NKs alone and in combination with mesothelin (MSLN)-CAR engineering and PKMYT1 inhibition.

RESULTS: BCL11B depletion enabled the generation of CD56CD16 1 F-NKs with potent cytotoxicity and elevated NKG2D and CX3CR1 expression. Site-specific integration of a mesothelin (MSLN)-CAR into BCL11B locus generated MSLN-1 F-NKs with stable antigen specific activity. A genome-wide screen identified PKMYT1 as a modulator of tumor resistance to NK cell-mediated killing; its inhibition by RP6306 upregulated NKG2D ligands (MICA/B) and CX3CL1, sensitizing PDACs to 1 F-NK cytotoxicity. In PDAC xenograft models, 1 F-NKs alone or combined with CAR engineering and RP6306 significantly reduced tumor growth and prolonged survival. Notably, this triple combination elicited a synergistic antitumor effect, outperforming each monotherapy or dual combination.

CONCLUSIONS: This study presents a synergistic immunotherapy platform that integrates NK reprogramming, CAR engineering, and tumor sensitization. The combinatorial approach significantly enhances antitumor efficacy in PDAC and offers a promising strategy for overcoming immune resistance in solid tumors.

**中文摘要译文：**
背景：胰腺导管腺癌（PDAC）是一种致命的恶性肿瘤，其特征为致密的促纤维增生性基质、免疫抑制性肿瘤微环境（TME）以及对标准疗法的耐药性。基于自然杀伤（NK）细胞的免疫疗法因其在PDAC中持久性、浸润能力和功能受损而显示出有限的疗效。

方法：我们建立了一种直接重编程策略，通过在人外周血单个核细胞（PBMCs）中使用shRNA或CRISPR/Cas9技术，靶向T细胞谱系定向所必需的转录因子BCL11B，从而生成细胞毒性NK细胞（1 F-NKs）。一项全基因组CRISPR/Cas9筛选确定了肿瘤内在的NK细胞耐药性调节因子。功能性与体内研究评估了1 F-NKs单独使用以及与间皮素（MSLN）-CAR工程化和PKMYT1抑制剂联合使用时的疗效。

结果：BCL11B耗竭能够生成具有强效细胞毒性以及NKG2D和CX3CR1表达水平升高的CD56CD16 1 F-NKs。将间皮素（MSLN）-CAR定点整合到BCL11B基因座，生成了具有稳定抗原特异性活性的MSLN-1 F-NKs。一项全基因组筛选将PKMYT1鉴定为肿瘤对NK细胞介导的杀伤产生耐药性的调节因子；使用RP6306抑制PKMYT1可上调NKG2D配体（MICA/B）和CX3CL1，从而使PDAC对1 F-NKs的细胞毒性作用敏感。在PDAC异种移植模型中，1 F-NKs单独使用或与CAR工程化和RP6306联合使用，均能显著抑制肿瘤生长并延长生存期。值得注意的是，这种三联组合疗法产生了协同抗肿瘤效应，其效果优于任何一种单一疗法或双重组合疗法。

结论：本研究提出了一个整合了NK细胞重编程、CAR工程化和肿瘤增敏的协同免疫治疗平台。该组合方法显著增强了在PDAC中的抗肿瘤疗效，并为克服实体瘤的免疫耐药性提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在针对难治性胰腺导管腺癌（PDAC）开发一种创新的细胞免疫治疗策略。研究团队通过耗竭T细胞关键转录因子BCL11B，成功地将外周血单核细胞直接重编程为高活性的NK细胞，并进一步通过CAR工程化技术增强其靶向性。核心发现是，这种重编程的CAR-NK细胞与一种能使肿瘤对NK细胞攻击更敏感的药物（PKMYT1抑制剂）相结合，在临床前模型中展现了强大的协同抗肿瘤效应。这项工作巧妙地整合了细胞重编程、靶向工程化和肿瘤增敏三大前沿技术，构建了一个“三位一体”的协同治疗平台，为攻克PDAC等实体瘤的免疫耐药性问题提供了极具潜力的临床转化新思路。

---

## 21. 基于PLGA的聚合物纳米载体在结直肠癌治疗中的研究进展：通过可控递送策略克服化疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233827](https://pubmed.ncbi.nlm.nih.gov/41233827)
**期刊：** Molecular cancer
**PMID：** 41233827
**DOI：** 10.1186/s12943-025-02435-2

### 第一部分 原文与翻译

**英文原标题：** Advances in PLGA-based polymeric nanocarriers for colorectal cancer therapy: overcoming chemoresistance through controlled delivery strategies.

**英文摘要原文：**
Colorectal cancer (CRC) is among the most prevalent malignancies globally, with a notably higher incidence in men. Despite the availability of multiple chemotherapeutic options, clinical efficacy remains limited due to poor drug solubility, restricted intestinal absorption, rapid systemic clearance, and multidrug resistance. Poly(lactic-co-glycolic acid) (PLGA), a well-established biodegradable and biocompatible copolymer, has gained significant attention for its potential in developing advanced drug delivery systems. Its tuneable degradation kinetics governed by the lactic-to-glycolic acid ratio enable precise modulation of drug release profiles. PLGA-based nanocarriers offer several therapeutic advantages, including improved solubility, extended colonic retention, and targeted delivery of anticancer agents. Furthermore, surface functionalization with copolymers, ligands, or stimuli-responsive moieties has demonstrated enhanced cellular uptake, tumor specificity, and cytotoxicity against CRC cells. This review highlights the recent developments in the synthesis, functional design, and biomedical application of PLGA nanocarriers in CRC treatment, emphasizing their role in overcoming key challenges such as chemoresistance and off-target toxicity. These advancements underscore the potential of PLGA-based polymeric systems in enhancing the therapeutic index and translational viability of anticancer therapies.

**中文摘要译文：**
结直肠癌（CRC）是全球最常见的恶性肿瘤之一，其在男性中的发病率显著更高。尽管有多种化疗方案可供选择，但由于药物溶解性差、肠道吸收受限、全身清除快以及多重耐药性等问题，其临床疗效仍然有限。聚乳酸-羟基乙酸共聚物（PLGA）作为一种成熟的生物可降解和生物相容性共聚物，因其在开发先进给药系统方面的潜力而备受关注。其降解动力学可通过调节乳酸与乙醇酸的比例进行调控，从而实现对药物释放曲线的精确调控。基于PLGA的纳米载体具有多种治疗优势，包括改善药物溶解度、延长结肠滞留时间以及实现抗癌药物的靶向递送。此外，通过共聚物、配体或刺激响应性基团进行表面功能化，已被证明能增强结直肠癌细胞对药物的摄取、提高肿瘤特异性及细胞毒性。本综述重点介绍了基于PLGA的纳米载体在结直肠癌治疗中的合成、功能设计及生物医学应用的最新进展，并强调了其在克服化疗耐药和脱靶毒性等关键挑战中的作用。这些进展凸显了基于PLGA的聚合物系统在提高抗癌疗法的治疗指数和临床转化潜力方面的巨大价值。

### 第二部分 AI 大师评价

本文是一篇综述，旨在系统性总结基于PLGA（聚乳酸-羟基乙酸共聚物）的纳米载体在结直肠癌治疗领域的最新进展。文章聚焦于如何通过功能化设计与可控递送策略，利用这种生物相容性材料来克服传统化疗面临的耐药性、溶解性差及脱靶毒性等核心挑战。其重要价值在于为开发新型、高效的结直肠癌靶向治疗方案提供了理论依据和前沿视角，对推动该领域药物递送系统的临床转化具有重要的指导意义。

---

## 22. 通过CD30共刺激与NF-κB信号通路增强CAR-T细胞的疗效与持久性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233815](https://pubmed.ncbi.nlm.nih.gov/41233815)
**期刊：** Molecular cancer
**PMID：** 41233815
**DOI：** 10.1186/s12943-025-02446-z

### 第一部分 原文与翻译

**英文原标题：** Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-κB signaling.

**英文摘要原文：**
Although chimeric antigen receptor (CAR)-redirected T lymphocytes have achieved unprecedented clinical responses in hematologic neoplasms, their role in solid tumors still needs to be improved. To overcome current limitations, we rationally designed a next-generation CAR-T cell construct incorporating autonomous costimulatory signaling pathways that operate independently of tumor antigen engagement, thus faithfully emulating physiological T cell activation paradigms. We screened seven costimulatory receptors from the TNF receptor superfamily and identified that CD30 is the most effective enhancer of CAR-T cell function. Subsequent structural analysis revealed that the intracellular domain (ICD) of CD30 is primarily responsible for its costimulatory activity. Our data showed that these CAR-T cells co-expressing CD30 ICD have stronger proliferation ability and cytokine secretion function. The results of in vitro experiments showed that CD30 signaling improved the cytotoxicity of CAR-T cells and reduced the expression of exhaustion-related markers. In mouse models of orthotopic renal cancer, lung metastasis, and hematologic malignancies, these CAR-T cells showed better expansion capability and superior antitumor activity. Sequencing results suggest that CD30 signaling may enhance the function of CAR-T cells by increasing the activation of the nuclear factor κB (NF-κB) pathway. Further mechanistic experiments confirmed that the NF-κB pathway is significantly activated in CAIX.CD30(ICD) CAR-T cells compared to CAIX CAR-T cells. Reversal experiments demonstrated that NF-κB pathway inhibitors can reverse the effector function of CAIX.CD30(ICD) CAR-T cells, while CAIX-IKKβ CAR-T cells with self-activated NF-κB pathway also exhibit significant functional advantages. By integrating autonomous costimulatory signaling, we demonstrated improved CAR-T cell persistence, proliferation, and antitumor activity across multiple preclinical models, highlighting the therapeutic potential of this approach for both hematologic malignancies and solid tumors.

**中文摘要译文：**
尽管嵌合抗原受体（CAR）T细胞在血液系统肿瘤中取得了前所未有的临床疗效，但其在实体瘤中的作用仍有待提升。为克服现有局限，我们合理设计了一种新一代CAR-T细胞构建体，其整合了独立于肿瘤抗原结合的自主共刺激信号通路，从而忠实模拟生理性的T细胞活化模式。我们筛选了TNF受体超家族中的七种共刺激受体，并发现CD30是增强CAR-T细胞功能最有效的分子。随后的结构分析揭示，CD30的胞内结构域（ICD）是其共刺激活性的主要来源。我们的数据显示，共表达CD30 ICD的CAR-T细胞具有更强的增殖能力和细胞因子分泌功能。体外实验结果表明，CD30信号传导能提高CAR-T细胞的细胞毒性，并降低耗竭相关标志物的表达。在原位肾癌、肺转移以及血液恶性肿瘤的小鼠模型中，这些CAR-T细胞展现出更佳的扩增能力和更优越的抗肿瘤活性。测序结果提示，CD30信号可能通过增强核因子κB（NF-κB）通路的激活来提升CAR-T细胞的功能。进一步的机制实验证实，与CAIX CAR-T细胞相比，CAIX.CD30(ICD) CAR-T细胞中的NF-κB通路被显著激活。逆转实验证明，NF-κB通路抑制剂可以逆转CAIX.CD30(ICD) CAR-T细胞的效应功能，而自主激活NF-κB通路的CAIX-IKKβ CAR-T细胞也表现出显著的功能优势。通过整合自主共刺激信号，我们在多种临床前模型中证实了CAR-T细胞的持久性、增殖能力和抗肿瘤活性的改善，凸显了该策略在治疗血液恶性肿瘤和实体瘤方面的潜力。

### 第二部分 AI 大师评价

本研究旨在解决CAR-T细胞疗法在实体瘤中效果不佳及持久性差的核心难题。研究团队创新性地设计了一种整合了CD30自主共刺激信号的新一代CAR-T细胞，通过筛选发现CD30的胞内结构域能最有效地增强CAR-T细胞功能。关键发现是，CD30通过激活NF-κB信号通路，显著提升了CAR-T细胞的增殖、抗肿瘤活性和持久性。这项研究为开发更强效的CAR-T疗法提供了新的设计思路和作用靶点，对推动实体瘤免疫治疗具有重要的临床转化价值。

---

## 23. 免疫检查点在调节癌干细胞抗肿瘤免疫应答中的作用：癌症治疗的启示与展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233805](https://pubmed.ncbi.nlm.nih.gov/41233805)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41233805
**DOI：** 10.1186/s13046-025-03514-4

### 第一部分 原文与翻译

**英文原标题：** The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy.

**英文摘要原文：**
Cancer stem cells (CSCs) are a minor subpopulation of tumor cells characterized by self-renewal capacity and stemness features and are responsible for tumor progression and therapy resistance. Several studies have shown that CSCs possess immunomodulatory properties that allow them to evade from immune responses. One of the mechanisms by which CSCs can escape from immune cells recognition and killing is represented by the overexpression of immune checkpoints (ICPs). The observation that cancer patients may still display or acquire resistance to immunotherapy despite targeting the PD-1/PD-L1 axis, highlights the importance of other ICPs as potential mediators of immune resistance. In this review, we summarize the immunomodulatory properties of CSCs and comprehensively discuss the crosstalk between these cells and selected ICPs (i.e., B7-H3, B7-H4, CD200 and CD155, VISTA, TIGIT, CD47, CD70, CEACAMs, and galectins) that are thought to be involved in CSC mediated immune evasion. Open questions regarding the immunological profile of CSCs, especially in relation to ICPs expression and their underlying regulatory mechanisms, are also addressed. Improved immunological profiling of CSCs will contribute to the identification of prognostic and predictive biomarkers for cancer patients and the development of effective therapeutic interventions that may lead to the eradication of malignant tumors.

**中文摘要译文：**
癌干细胞（CSCs）是肿瘤细胞中一个具有自我更新能力和干性特征的少数亚群，是肿瘤进展和治疗耐药的原因。多项研究表明，CSCs具有免疫调节特性，使其能够逃避免疫应答。CSCs逃避免疫细胞识别和杀伤的机制之一是免疫检查点（ICPs）的过表达。尽管靶向PD-1/PD-L1轴，癌症患者仍可能表现出或产生对免疫治疗的耐药性，这一现象凸显了其他ICPs作为免疫耐药潜在介质的重要性。在这篇综述中，我们总结了CSCs的免疫调节特性，并全面讨论了这些细胞与被认为参与CSC介导的免疫逃逸的特定ICPs（即B7-H3、B7-H4、CD200和CD155、VISTA、TIGIT、CD47、CD70、CEACAMs和半乳糖凝集素）之间的相互作用。文章还探讨了关于CSCs免疫学特征的开放性问题，特别是与其ICPs表达及其潜在调控机制相关的问题。改进CSCs的免疫学分析将有助于为癌症患者识别预后和预测性生物标志物，并开发可能根除恶性肿瘤的有效治疗干预措施。

### 第二部分 AI 大师评价

这篇综述深入探讨了癌干细胞（CSCs）通过表达多种免疫检查点（ICPs）来逃避免疫系统监视的核心机制。文章超越了经典的PD-1/PD-L1轴，系统性地总结了B7-H3、VISTA、TIGIT等多个新兴ICPs在CSCs介导的免疫逃逸中的作用，揭示了免疫治疗耐药性的复杂网络。该综述不仅为理解肿瘤免疫微环境提供了全面的视角，也为开发针对CSCs的新型免疫治疗策略和寻找潜在的生物标志物指明了重要方向，具有显著的科研和临床转化价值。

---

## 24. 通过双向阻断CXCL12/CXCR4轴增强癌症纳米疫苗以抑制三阴性乳腺癌的复发和转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233789](https://pubmed.ncbi.nlm.nih.gov/41233789)
**期刊：** Molecular cancer
**PMID：** 41233789
**DOI：** 10.1186/s12943-025-02496-3

### 第一部分 原文与翻译

**英文原标题：** The enhanced cancer nanovaccine by bidirectionally blocking CXCL12/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

本研究旨在开发一种增强型癌症纳米疫苗，用于抑制侵袭性强的三阴性乳腺癌的复发与转移。其核心创新策略在于通过双向阻断关键的CXCL12/CXCR4信号轴，可能旨在重塑肿瘤免疫微环境，从而增强疫苗的抗肿瘤效果。尽管摘要缺失，但该标题揭示了一种颇具前景的免疫治疗新思路，即通过将免疫激活（疫苗）与靶向微环境调控（阻断信号轴）相结合，为治疗高复发风险的三阴性乳腺癌提供了重要的潜在临床转化价值。

---

## 25. Blinatumomab用于高危首次复发的B细胞前体急性淋巴细胞白血病患儿巩固治疗的随机、多中心III期研究：最终5年随访分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233549](https://pubmed.ncbi.nlm.nih.gov/41233549)
**期刊：** Leukemia
**PMID：** 41233549
**DOI：** 10.1038/s41375-025-02800-6

### 第一部分 原文与翻译

**英文原标题：** Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究是一项针对高危首次复发B细胞前体急性淋巴细胞白血病（B-ALL）患儿的III期随机多中心临床试验，旨在评估Blinatumomab（一种双特异性T细胞衔接抗体）作为巩固治疗的长期疗效。通过最终的5年随访数据分析，本研究为Blinatumomab在该高危、难治群体中的应用提供了最高级别的循证医学证据。其研究结果对于确立Blinatumomab在复发B-ALL患儿治疗路径中的核心地位、优化治疗策略具有决定性的临床指导意义，并可能重新定义该领域的标准治疗方案。

---

## 26. 对一例猪到人脑死亡受者肾脏异种移植的多组学分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233547](https://pubmed.ncbi.nlm.nih.gov/41233547)
**期刊：** Nature
**PMID：** 41233547
**DOI：** 10.1038/s41586-025-09846-7

### 第一部分 原文与翻译

**英文原标题：** Multi-omics analysis of a pig-to-human decedent kidney xenotransplant.

**英文摘要原文：**
Organ shortage remains a major challenge in transplantation, and gene-edited pig organs offer a promising solution. Despite gene-editing, the immune reactions following xenotransplantation can still cause transplant failure. To understand the immunological response of a pig-to-human kidney xenotransplantation, we conducted large-scale multi-omics profiling of the xenograft and the host's blood over a 61-day procedure in a brain-dead human (decedent) recipient. Blood plasmablasts, natural killer (NK) cells, and dendritic cells increased between postoperative day (POD)10 and 28, concordant with expansion of IgG/IgA B-cell clonotypes, and subsequent biopsy-confirmed antibody-mediated rejection (AbMR) at POD33. Human T-cell frequencies increased from POD21 and peaked between POD33-49 in the blood and xenograft, coinciding with T-cell receptor diversification, expansion of a restricted TRBV2/J1 clonotype and histological evidence of a combined AbMR and cell-mediated rejection at POD49. At POD33, the most abundant human immune population in the graft was CXCL9+ macrophages, aligning with IFN-γ-driven inflammation and a Type I immune response. In addition, we see evidence of interactions between activated pig-resident macrophages and infiltrating human immune cells. Xenograft tissue showed pro-fibrotic tubular and interstitial injury, marked by S100A6, SPP1 (Osteopontin), and COLEC11, at POD21-POD33. Proteomics profiling revealed human and pig complement activation, with decreased human component after AbMR therapy with complement inhibition. Collectively, these data delineate the molecular orchestration of human immune responses to a porcine kidney, revealing potential immunomodulatory targets for improving xenograft survival.

**中文摘要译文：**
器官短缺仍然是移植领域的一大挑战，而基因编辑猪器官提供了一种有前景的解决方案。尽管进行了基因编辑，异种移植后的免疫反应仍可能导致移植失败。为了解猪到人肾脏异种移植的免疫反应，我们对一名脑死亡人类（遗体）受者进行了为期61天的手术，并在此期间对异种移植物和宿主血液进行了大规模多组学分析。术后第10天至第28天，血液中的浆母细胞、自然杀伤（NK）细胞和树突状细胞增加，这与IgG/IgA B细胞克隆型的扩增相一致，并随后在术后第33天经活检证实发生抗体介导的排斥反应（AbMR）。人类T细胞频率从术后第21天开始增加，在术后第33至49天于血液和异种移植物中达到峰值，这与T细胞受体的多样化、一个受限的TRBV2/J1克隆型的扩增以及术后第49天出现AbMR与细胞介导排斥反应相结合的组织学证据相吻合。在术后第33天，移植物中最丰富的人类免疫细胞群体是CXCL9+巨噬细胞，这与IFN-γ驱动的炎症和I型免疫反应一致。此外，我们还观察到活化的猪源性巨噬细胞与浸润的人类免疫细胞之间存在相互作用的证据。在术后第21至33天，异种移植物组织表现出以S100A6、SPP1（骨桥蛋白）和COLEC11为标志的促纤维化肾小管和间质损伤。蛋白质组学分析揭示了人类和猪的补体均被激活，而在采用补体抑制治疗AbMR后，人类补体成分有所减少。总而言之，这些数据描绘了人类对猪肾免疫反应的分子调控机制，揭示了提高异种移植物存活率的潜在免疫调节靶点。

### 第二部分 AI 大师评价

本研究通过对一例猪-人肾脏异种移植案例进行为期61天的多组学分析，旨在深入揭示移植后人体免疫反应的复杂分子机制。研究创新性地在脑死亡受者模型中结合了转录组、蛋白质组等高通量技术，全面描绘了从抗体介导到细胞介导排斥反应的动态过程，并精确定位了关键的免疫细胞亚群（如浆母细胞、T细胞和巨噬细胞）和分子信号通路（如补体激活和IFN-γ驱动的炎症）。该研究不仅为理解异种移植排斥反应提供了前所未有的高分辨率图谱，更重要的是，它揭示了多个潜在的免疫干预新靶点，为优化免疫抑制方案、提高异种器官移植的长期存活率提供了关键的科学依据和转化价值。

---

## 27. 猪到人逝者肾脏异种移植的生理学和免疫学研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233546](https://pubmed.ncbi.nlm.nih.gov/41233546)
**期刊：** Nature
**PMID：** 41233546
**DOI：** 10.1038/s41586-025-09847-6

### 第一部分 原文与翻译

**英文原标题：** Physiology and immunology of pig-to-human decedent kidney xenotransplant.

**英文摘要原文：**
Xenotransplantation of genetically-modified pig kidneys offers a solution to the scarcity of organs for end-stage renal disease patients. We performed a 61-day alpha-Gal knock-out pig kidney and thymic autograft transplant into a nephrectomized brain-dead human using clinically approved immunosuppression, without CD40 blockade or additional genetic modification. Hemodynamic and electrolyte stability and dialysis independence were achieved. Post-operative day (POD) 10 biopsies revealed glomerular IgM and IgA deposition, activation of early complement components and mesangiolysis with stable renal function without proteinuria, a phenotype not seen in allotransplantation. On POD 33, an abrupt increase in serum creatinine was associated with antibody-mediated rejection and increased donor-specific IgG. Plasma exchange, C3/C3b inhibition and rabbit anti-thymocyte globulin (rATG), completely reversed xenograft rejection. Pre-existing donor-reactive T cell clones expanded progressively in the circulation post-transplant, acquired an effector transcriptional profile and were detected in the POD 33 rejecting xenograft prior to rATG treatment. This study provides the first long-term physiologic, immunologic, and infectious disease monitoring of a pig-to-human kidney xenotransplant and indicates that pre-existing xenoreactive T cells and induced antibodies to unknown epitope(s) present a major challenge, despite significant immunosuppression. It also demonstrates that a minimally gene-edited pig kidney can support long-term life-sustaining physiologic functions in a human.

**中文摘要译文：**
对于终末期肾病患者而言，基因修饰猪肾的异种移植为器官短缺问题提供了一种解决方案。我们采用临床批准的免疫抑制方案，在未使用CD40阻断剂或其他额外基因修饰的情况下，将一枚敲除了α-Gal基因的猪肾及胸腺移植物移植到一名已行肾切除的脑死亡人体内，并维持了61天。移植后，受体实现了血流动力学和电解质的稳定，并脱离了透析。术后第10天的活检显示，存在肾小球IgM和IgA沉积、早期补体成分激活以及系膜溶解，但肾功能稳定且无蛋白尿——这一表型在同种异体移植中未曾见过。术后第33天，血清肌酐水平突然升高，这与抗体介导的排斥反应及供体特异性IgG的增加有关。通过血浆置换、C3/C3b抑制以及使用兔抗胸腺细胞球蛋白（rATG），异种移植物的排斥反应被完全逆转。移植前已存在的供体反应性T细胞克隆在移植后于循环系统中逐渐扩增，获得了效应T细胞的转录特征，并在使用rATG治疗前于术后第33天发生排斥反应的异种移植物中被检测到。本研究首次对猪到人肾脏异种移植进行了长期的生理、免疫及传染病监测，并指出，尽管采用了强效的免疫抑制方案，预存的异种反应性T细胞和针对未知抗原表位诱导产生的抗体仍是主要的挑战。研究同时证明，仅经过最低限度基因编辑的猪肾能够在人体内长期维持生命所需的生理功能。

### 第二部分 AI 大师评价

本研究通过将一枚仅敲除α-Gal基因的猪肾移植入脑死亡人体模型并维持长达61天，深入探究了异种移植的长期生理及免疫学反应。核心发现是，该猪肾能长期维持生命功能，但术后约一月时发生了可被成功逆转的、由抗体与T细胞共同介导的排斥反应。此项研究是迄今为止持续时间最长的猪-人肾脏移植记录，其创新性在于证实了最少基因编辑的猪器官的巨大潜力，并为理解和应对移植后复杂的细胞与体液免疫排斥挑战（特别是针对非α-Gal抗原的反应）提供了宝贵的临床前证据。

---

## 28. 己糖激酶2（HK2）的一种非葡萄糖激酶依赖性活性通过磷酸化RIPK1来抑制TNF诱导的细胞死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233370](https://pubmed.ncbi.nlm.nih.gov/41233370)
**期刊：** Nature communications
**PMID：** 41233370
**DOI：** 10.1038/s41467-025-64939-1

### 第一部分 原文与翻译

**英文原标题：** A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1.

**英文摘要原文：**
Tumor necrosis factor (TNF)-induced RIPK1-mediated cell death is implicated in various human diseases. However, the mechanisms RIPK1-mediated cell death is regulated by metabolic processes remain unclear. Here, we identify hexokinase 2 (HK2), a critical regulator of glycolysis, as a suppressor of TNF-induced RIPK1 kinase-dependent cell death through its non-metabolic function. HK2 inhibits RIPK1 kinase activity through constitutively phosphorylation at serine 32 of RIPK1. Inhibition of RIPK1 S32-phosphorylation results in RIPK1 kinase activation and subsequent cell death in response to TNFα stimulation. We further show that HK2 is elevated under pathological conditions including liver ischemia-reperfusion (IR) injury and hepatocellular carcinoma (HCC) via the transcriptional factor HMGA1. Moreover, the upregulation of HK2 in the liver confers protection against liver IR injury mediated by RIPK1 kinase, while depleting HK2 in HCC cells enhances TNFα-induced cell death and synergistically improves the efficacy of anti-PD1 therapy in an HCC model. Thus, the findings reveal a potential therapeutic avenue for RIPK1-related diseases through manipulating HK2 non-metabolic function.

**中文摘要译文：**
肿瘤坏死因子（TNF）诱导的RIPK1介导的细胞死亡与多种人类疾病有关。然而，RIPK1介导的细胞死亡受代谢过程调控的具体机制尚不清楚。在本研究中，我们发现糖酵解的关键调控因子己糖激酶2（HK2）能通过其非代谢功能，抑制TNF诱导的RIPK1激酶依赖性细胞死亡。HK2通过对RIPK1的丝氨酸32位点进行组成性磷酸化来抑制其激酶活性。抑制RIPK1 S32位点的磷酸化会导致在TNFα刺激下RIPK1激酶的激活及随后的细胞死亡。我们进一步表明，在肝脏缺血再灌注（IR）损伤和肝细胞癌（HCC）等病理条件下，HK2通过转录因子HMGA1的作用而表达上调。此外，肝脏中HK2的上调能够抵抗由RIPK1激酶介导的肝脏IR损伤；而在HCC细胞中耗尽HK2则能增强TNFα诱导的细胞死亡，并在一个HCC模型中协同提高抗PD-1疗法的疗效。因此，这些发现揭示了通过调控HK2的非代谢功能来治疗RIPK1相关疾病的潜在治疗途径。

### 第二部分 AI 大师评价

本研究旨在阐明糖酵解关键酶HK2在调控肿瘤坏死因子（TNF）诱导的细胞死亡中的非代谢作用。研究通过一系列生化及细胞实验，结合肝脏缺血再灌注损伤和肝癌动物模型，关键性地发现HK2能够以不依赖其葡萄糖激酶活性的方式，直接磷酸化RIPK1蛋白的S32位点，从而抑制其激酶活性并阻止细胞死亡。这项发现创新性地揭示了代谢酶HK2的非经典功能，并将其与细胞死亡和炎症信号通路直接关联，为开发针对RIPK1相关疾病（如肝损伤和癌症）的新型治疗策略——即靶向HK2的非代谢功能——提供了重要的理论依据和潜在靶点。

---

## 29. 寡聚体胱抑素C通过与抑制性受体相互作用支持髓系细胞的免疫抑制活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233352](https://pubmed.ncbi.nlm.nih.gov/41233352)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41233352
**DOI：** 10.1038/s41392-025-02462-x

### 第一部分 原文与翻译

**英文原标题：** Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors.

**英文摘要原文：**
Amyloid proteins are linked to various diseases; however, their functional roles in immunity and cancer remain unclear. Here, we establish a direct link between oligomeric cystatin C-a cysteine cathepsin inhibitor and a well-characterized amyloidogenic protein-within the tumor microenvironment and the immune inhibitory receptors LILRB2 and LILRB5 on myeloid cells. We demonstrated that human LILRB2 and LILRB5, along with their murine counterpart PIRB, serve as functional receptors for cystatin C oligomers. Engagement of these inhibitory receptors by oligomeric cystatin C enhances the immunosuppressive activity of myeloid cells, leading to T-cell suppression and tumor progression. Deletion of the CST3 gene, which encodes cystatin C, in host mice and tumor cells impaired tumor growth, whereas its overexpression accelerated cancer progression in LILRB2 and LILRB5 transgenic mice. Mechanistically, cystatin C-LILRB2 signaling is driven by both canonical phosphatases and the enhanced TGF-β pathway. Additionally, we identified interactions between LILRB receptors and transthyretin oligomers, another amyloid linked to transthyretin amyloidosis, suggesting a broader paradigm of amyloid-LILRB interactions. Our findings reveal an unexpected role of oligomeric cystatin C in enhancing myeloid cell immunosuppression, expand the functional spectrum of amyloid proteins and underscore the importance of these proteins in immune evasion and cancer development.

**中文摘要译文：**
淀粉样蛋白与多种疾病相关；然而，它们在免疫和癌症中的功能作用仍不清楚。在本研究中，我们建立了肿瘤微环境中的寡聚体胱抑素C（一种半胱氨酸组织蛋白酶抑制剂和一种特征明确的淀粉样蛋白）与髓系细胞上的免疫抑制性受体LILRB2和LILRB5之间的直接联系。我们证明了人类LILRB2和LILRB5及其鼠类对应物PIRB可作为胱抑素C寡聚体的功能性受体。寡聚体胱抑素C与这些抑制性受体的结合增强了髓系细胞的免疫抑制活性，导致T细胞抑制和肿瘤进展。在宿主小鼠和肿瘤细胞中删除编码胱抑素C的CST3基因会损害肿瘤生长，而在LILRB2和LILRB5转基因小鼠中其过表达则会加速癌症进展。从机制上讲，胱抑素C-LILRB2信号传导是由经典的磷酸酶和增强的TGF-β通路共同驱动的。此外，我们还确定了LILRB受体与甲状腺素运载蛋白寡聚体（另一种与甲状腺素运载蛋白淀粉样变性相关的淀粉样蛋白）之间的相互作用，这提示了淀粉样蛋白-LILRB相互作用可能是一种更广泛的模式。我们的研究结果揭示了寡聚体胱抑素C在增强髓系细胞免疫抑制中的一个意想不到的作用，扩展了淀粉样蛋白的功能谱，并强调了这些蛋白在免疫逃逸和癌症发展中的重要性。

### 第二部分 AI 大师评价

该研究旨在阐明寡聚体胱抑素C在肿瘤免疫微环境中的具体作用。研究通过一系列体内外实验，关键性地发现寡聚体胱抑素C能直接与髓系细胞上的抑制性受体LILRB2/LILRB5结合，从而增强其免疫抑制功能，促进肿瘤进展。这项工作的创新之处在于揭示了淀粉样蛋白在肿瘤免疫逃逸中的一个全新机制，将胱抑素C-LILRB轴确立为潜在的癌症免疫治疗新靶点，并为理解淀粉样蛋白与免疫系统的相互作用提供了更广阔的视角。

---

## 30. 非凋亡性Caspase-8在调控重症SARS-CoV-2感染期间的过度炎症反应中起关键作用。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233351](https://pubmed.ncbi.nlm.nih.gov/41233351)
**期刊：** Nature communications
**PMID：** 41233351
**DOI：** 10.1038/s41467-025-65098-z

### 第一部分 原文与翻译

**英文原标题：** Non-apoptotic caspase-8 is critical for orchestrating exaggerated inflammation during severe SARS-CoV-2 infection.

**英文摘要原文：**
Inflammation and excess cytokine release are hallmarks of severe COVID-19. While programmed cell death is known to drive inflammation, its role in SARS-CoV-2 pathogenesis remains unclear. Using gene-targeted murine COVID-19 models, we here find that caspase-8 is critical for cytokine release and inflammation. Loss of caspase-8 reduces disease severity and viral load in mice, and this occurs independently of its apoptotic function. Instead, reduction in SARS-CoV-2 pathology is linked to decreased IL-1β levels and inflammation. Loss of pyroptosis and necroptosis mediators in gene-targeted animals provides no additional benefits in mitigating disease outcomes beyond that conferred by loss of caspase-8. Spatial transcriptomic and proteomic analyses of caspase-8-deficient mice confirm that improved outcomes are due to reduced pro-inflammatory responses, rather than changes in cell death signalling. Elevated expression of caspase-8 and cFLIP in infected lungs, alongside caspase-8-mediated cleavage of N4BP1, a suppressor of NF-kB signalling, indicates a role of this signalling axis in pathological inflammation. Collectively, these findings highlight non-apoptotic functions of caspase-8 as a driver of severe COVID-19 through modulation of inflammation, not through the induction of apoptosis.

**中文摘要译文：**
炎症和细胞因子过度释放是重症COVID-19的标志。虽然程序性细胞死亡已知能驱动炎症，但其在SARS-CoV-2发病机制中的作用仍不清楚。本研究利用基因靶向的COVID-19小鼠模型发现，caspase-8对细胞因子释放和炎症至关重要。caspase-8的缺失可降低小鼠的疾病严重程度和病毒载量，且此过程独立于其凋亡功能。相反，SARS-CoV-2病理变化的减轻与IL-1β水平和炎症的降低有关。在基因靶向动物中，焦亡和坏死性凋亡介质的缺失，在减轻疾病结局方面，并未提供超出caspase-8缺失所带来的额外益处。对caspase-8缺陷小鼠的空间转录组学和蛋白质组学分析证实，结局的改善是由于促炎反应减弱，而非细胞死亡信号的改变。受感染肺组织中caspase-8和cFLIP的表达升高，以及caspase-8介导的NF-kB信号抑制因子N4BP1的切割，表明该信号轴在病理性炎症中发挥作用。总而言之，这些发现凸显了caspase-8通过调节炎症而非诱导细胞凋亡来驱动重症COVID-19的非凋亡功能。

### 第二部分 AI 大师评价

本研究旨在阐明caspase-8在重症COVID-19过度炎症中的作用。研究团队巧妙地利用基因靶向小鼠模型，结合空间转录组学等前沿技术，发现caspase-8通过其非凋亡功能（而非诱导细胞死亡）加剧了炎症风暴和疾病严重性。其关键创新点在于揭示了caspase-8独立于细胞凋亡，通过切割NF-kB信号抑制因子N4BP1来放大炎症反应，为治疗重症COVID-19提供了新的潜在靶点。这一发现对于开发精准抗炎策略具有重要的临床和科研价值。

---

## 31. 用于激酶信号传导的定量多重和空间监测的蛋白质组学传感器

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233332](https://pubmed.ncbi.nlm.nih.gov/41233332)
**期刊：** Nature communications
**PMID：** 41233332
**DOI：** 10.1038/s41467-025-65950-2

### 第一部分 原文与翻译

**英文原标题：** Proteomic sensors for quantitative multiplexed and spatial monitoring of kinase signaling.

**英文摘要原文：**
Understanding kinase action requires precise quantitative measurements of their activity in vivo. In addition, the ability to capture spatial information of kinase activity is crucial to deconvolute complex signaling networks, interrogate multifaceted kinase actions, and assess drug effects or genetic perturbations. Here we develop a proteomic kinase activity sensor technique (ProKAS) for the analysis of kinase signaling using mass spectrometry. ProKAS is based on a tandem array of peptide sensors with amino acid barcodes that allow multiplexed analysis for spatial, kinetic, and screening applications. We engineered a ProKAS module to simultaneously monitor the activities of the DNA damage response kinases ATR, ATM, and CHK1 in response to genotoxic drugs, while also uncovering differences between these signaling responses in the nucleus, cytosol, and replication factories. Furthermore, we developed an in silico approach for the rational design of specific substrate peptides expandable to other kinases. Overall, ProKAS is a versatile system for systematically and spatially probing kinase action in cells.

**中文摘要译文：**
理解激酶的作用需要对其体内活性进行精确的定量测量。此外，捕获激酶活性的空间信息对于解析复杂的信号网络、探究激酶的多方面作用以及评估药物效应或遗传扰动至关重要。在此，我们开发了一种利用质谱技术分析激酶信号的蛋白质组学激酶活性传感器技术（ProKAS）。ProKAS基于带有氨基酸条形码的肽传感器串联阵列，可实现用于空间、动力学和筛选应用的多重分析。我们设计了一个ProKAS模块，以同时监测DNA损伤反应激酶ATR、ATM和CHK1对遗传毒性药物的响应活动，同时也揭示了这些信号响应在细胞核、细胞质和复制工厂之间的差异。此外，我们还开发了一种计算机模拟方法，用于合理设计可扩展至其他激酶的特异性底物肽。总而言之，ProKAS是一个能够系统性地、空间性地探测细胞内激酶作用的多功能系统。

### 第二部分 AI 大师评价

该研究旨在解决活细胞内激酶活性定量与空间定位的难题。研究团队开发了一种名为ProKAS的创新蛋白质组学传感器技术，该技术利用带条形码的肽传感器阵列和质谱分析，实现了对多种激酶活性的同步、空间分辨监测。其关键发现是成功揭示了DNA损伤反应激酶在细胞核、细胞质等不同亚细胞结构中的差异化激活模式。这项技术极具创新性，为系统性研究复杂信号网络提供了强大的新工具，在药物开发和基础生物学研究中具有巨大的应用潜力。

---

## 32. 实体瘤内的多细胞免疫生态型可预测免疫检查点抑制剂的真实世界治疗获益。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233329](https://pubmed.ncbi.nlm.nih.gov/41233329)
**期刊：** Nature communications
**PMID：** 41233329
**DOI：** 10.1038/s41467-025-65016-3

### 第一部分 原文与翻译

**英文原标题：** Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.

**英文摘要原文：**
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet predicting patient response remains a major challenge. Carcinoma ecotypes, which capture the cancer-immune interactions, show promise as prognostic biomarkers but remain untested in real-world settings. We compile and analyze the ORIEN Avatar ICI cohort of 1610 patients with matched gene expression data from a broader dataset of 14,997 individuals. Using EcoTyper-based immunophenotyping, we define ecotypes and assess their prognostic value across cancers, with a focused analysis in melanoma. Distinct cell states and ecotypes are consistently associated with survival outcomes across cancer types. We further develop a melanoma-specific ICI predictive model and validate it using data from the phase III ECOG-ACRIN E1609 trial as well as in external harmonized melanoma datasets. Together, these findings establish an ecotype-based framework and provide real-world evidence for their translational utility as clinically actionable biomarkers with prognostic and predictive value to guide ICI therapy.

**中文摘要译文：**
免疫检查点抑制剂（ICIs）已经改变了癌症治疗，但预测患者的反应仍然是一个重大挑战。捕获癌症-免疫相互作用的癌生态型，作为预后生物标志物显示出潜力，但在真实世界环境中尚未得到检验。我们汇编并分析了来自一个包含14,997人的更大数据集中的1610名患者的ORIEN Avatar ICI队列，这些患者拥有匹配的基因表达数据。我们使用基于EcoTyper的免疫分型方法定义了生态型，并评估了它们在不同癌症中的预后价值，同时重点分析了黑色素瘤。不同的细胞状态和生态型在各种癌症类型中均与生存结局持续相关。我们进一步开发了一个黑色素瘤特异性的ICI预测模型，并使用来自III期ECOG-ACRIN E1609试验的数据以及外部协调的黑色素瘤数据集对其进行了验证。总之，这些发现建立了一个基于生态型的框架，并为其作为具有预后和预测价值、可指导ICI治疗的临床可操作生物标志物的转化应用提供了真实世界的证据。

### 第二部分 AI 大师评价

该研究旨在验证“免疫生态型”作为预测免疫检查点抑制剂（ICI）治疗反应的生物标志物在真实世界中的应用价值。研究团队利用大规模真实世界队列数据，通过免疫分型技术识别出与生存结局相关的多细胞免疫生态型，并成功开发和验证了一个针对黑色素瘤的ICI疗效预测模型。这项工作的创新性在于，它首次在大型真实世界数据中证实了免疫生态型概念的临床转化潜力，为实现更精准的ICI个体化治疗提供了有力的证据和可行的分析框架。

---

## 33. qMaLioffG：一种基于绿色荧光寿命的基因编码指示剂，可实现细胞内ATP的定量成像

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233321](https://pubmed.ncbi.nlm.nih.gov/41233321)
**期刊：** Nature communications
**PMID：** 41233321
**DOI：** 10.1038/s41467-025-64946-2

### 第一部分 原文与翻译

**英文原标题：** qMaLioffG: a genetically encoded green fluorescence lifetime-based indicator enabling quantitative imaging of intracellular ATP.

**英文摘要原文：**
Genetically encoded indicators that can detect concentrations of metabolites and signalling molecules through fluorescence lifetime changes are gaining attention, because they expand the potential for quantitative imaging. These indicators offer advantages over conventional fluorescence intensity-based indicators by minimizing artifacts such as variations in indicator concentration, cellular morphological changes, and focus drift. However, the availability of fluorescence lifetime-based genetically encoded indicators remains limited, particularly those compatible with the widely used conventional 488 nm laser in microscopy. Here, we introduce qMaLioffG, a single green fluorescent protein-based ATP indicator that exhibits a substantial fluorescence lifetime shift (1.1 ns) within physiologically relevant ATP concentrations. This enables quantitative imaging of ATP levels in the cytoplasm and mitochondria under steady-state conditions across various cell types, providing insights into ATP distribution. We demonstrate that qMaLioffG can be used in multicellular systems, applying it to Drosophila brain and HeLa cell spheroids to reveal spatially heterogeneous ATP levels.

**中文摘要译文：**
通过荧光寿命变化来检测代谢物和信号分子浓度的基因编码指示剂正日益受到关注，因为它们扩展了定量成像的潜力。与传统的基于荧光强度的指示剂相比，这些指示剂通过最大限度地减少指示剂浓度变化、细胞形态改变和焦平面漂移等伪影，展现出其优势。然而，基于荧光寿命的基因编码指示剂的种类仍然有限，特别是那些与显微镜中广泛使用的传统488 nm激光器兼容的指示剂。在此，我们介绍了一种名为qMaLioffG的指示剂，这是一种基于单一绿色荧光蛋白的ATP指示剂，在生理相关的ATP浓度范围内表现出显著的荧光寿命偏移（1.1纳秒）。这使得在稳态条件下对多种细胞类型的细胞质和线粒体中的ATP水平进行定量成像成为可能，从而为洞察ATP分布提供了新见解。我们证明了qMaLioffG可用于多细胞系统，并将其应用于果蝇大脑和HeLa细胞球体，揭示了ATP水平在空间上的异质性。

### 第二部分 AI 大师评价

本研究旨在开发一种新型的、基于荧光寿命的基因编码ATP指示剂，以实现对细胞内ATP浓度的精确定量成像。研究团队成功构建了名为qMaLioffG的绿色荧光指示剂，其关键优势在于它能被常规的488nm激光器激发，且在生理ATP浓度范围内展现出显著的荧光寿命变化。该研究不仅成功应用于多种单细胞的细胞质与线粒体ATP水平的稳态测量，更在果蝇大脑和细胞球等多细胞系统中揭示了ATP分布的空间异质性。这项工作的创新性在于提供了一个克服传统强度型探针局限性的强大工具，极大地推动了在复杂生物系统中对能量代谢进行原位、定量研究的能力。

---

## 34. 热休克蛋白DNAJA2通过阻止胰岛素受体自发性内吞来控制胰岛素信号传导和葡萄糖稳态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41233317](https://pubmed.ncbi.nlm.nih.gov/41233317)
**期刊：** Nature communications
**PMID：** 41233317
**DOI：** 10.1038/s41467-025-64948-0

### 第一部分 原文与翻译

**英文原标题：** Heat shock protein DNAJA2 controls insulin signaling and glucose homeostasis by preventing spontaneous insulin receptor endocytosis.

**英文摘要原文：**
Dysregulation of heat shock protein DNAJA2 induces genomic instability and was consequently hypothesized to promote tumorigenesis. However, DNAJA2 knockout mice do not develop cancer but exhibit neonatal lethality and the underlying mechanism remains unknown. Here, we demonstrate that DNAJA2 maintains homeostatic glucose metabolism by regulating insulin signaling. Mechanistically, DNAJA2 binds to the insulin receptor (IR) and prevents adaptor protein 2 (AP2)-mediated spontaneous IR endocytosis by inhibiting the IR-AP2 interaction. Thus, DNAJA2 defects lead to reduced IR localization on the plasma membrane and suppression of the insulin-stimulated signaling cascade, thereby inhibiting glycogen synthesis and storage in the liver during embryogenesis, further resulting in neonatal lethality of DNAJA2-deficient mice. Analysis of public datasets reveals a strong association between DNAJA2 and metabolic phenotypes, including type 2 diabetes mellitus (T2DM) and obesity, in both humans and mice. In conclusion, our study elucidates the mechanism by which DNAJA2 regulates IR endocytosis, insulin signaling and glucose metabolism, shedding light on the pathogenesis of metabolic disorders.

**中文摘要译文：**
热休克蛋白DNAJA2的失调会诱导基因组不稳定性，因此曾被假设能促进肿瘤发生。然而，DNAJA2敲除小鼠并未患上癌症，反而表现出新生期致死，其潜在机制尚不清楚。在此，我们证明了DNAJA2通过调节胰岛素信号传导来维持葡萄糖代谢的稳态。从机制上讲，DNAJA2与胰岛素受体（IR）结合，并通过抑制IR-AP2的相互作用来阻止衔接蛋白2（AP2）介导的IR自发性内吞。因此，DNAJA2缺陷导致质膜上IR的定位减少，并抑制了胰岛素刺激的信号级联反应，从而在胚胎发生过程中抑制了肝脏的糖原合成与储存，进一步导致了DNAJA2缺陷小鼠的新生期致死。对公共数据集的分析显示，在人类和小鼠中，DNAJA2与包括2型糖尿病（T2DM）和肥胖在内的代谢表型密切相关。总之，我们的研究阐明了DNAJA2调控IR内吞、胰岛素信号和葡萄糖代谢的机制，为代谢性疾病的发病机制提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在揭示热休克蛋白DNAJA2在小鼠新生期致死中的未知作用机制。研究通过分子生物学实验和动物模型，创新性地发现DNAJA2并非主要通过调控基因组稳定性影响生存，而是通过与胰岛素受体（IR）结合，抑制其自发性内吞，从而维持胰岛素信号通路的正常功能和葡萄糖稳态。这一发现不仅阐明了DNAJA2缺失导致新生期致死的根本原因，更重要的是，它揭示了DNAJA2在代谢性疾病（如2型糖尿病和肥胖）中的潜在关键角色，为相关疾病的治疗提供了新的分子靶点。

---

## 35. 脱离背景的癌基因：癌症基因摆脱染色体的调控束缚

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41232000](https://pubmed.ncbi.nlm.nih.gov/41232000)
**期刊：** Science (New York, N.Y.)
**PMID：** 41232000
**DOI：** 10.1126/science.aec9588

### 第一部分 原文与翻译

**英文原标题：** Oncogenes out of context: Cancer genes break free from the regulatory constraints of chromosomes.

**英文摘要原文：**
Cancer genes break free from the regulatory constraints of chromosomes.

**中文摘要译文：**
癌症基因摆脱了染色体的调控束缚。

### 第二部分 AI 大师评价

该研究聚焦于癌基因如何摆脱其染色体环境的常规调控。其核心发现是，癌基因能够脱离其在染色体上的原始位置（可能通过形成染色体外DNA等形式），从而逃避正常的基因组调控网络，实现异常扩增和表达。这一观点颠覆了传统上将癌基因固定于染色体线性序列的认知，为理解肿瘤的快速进化、高度异质性及耐药性提供了革命性的新视角，并为开发靶向这些“法外”癌基因的新型疗法带来了希望。

---

## 36. cDC1s中Ms4a7的表达决定了交叉呈递和抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231994](https://pubmed.ncbi.nlm.nih.gov/41231994)
**期刊：** Science (New York, N.Y.)
**PMID：** 41231994
**DOI：** 10.1126/science.ady5362

### 第一部分 原文与翻译

**英文原标题：** Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity.

**英文摘要原文：**
Conventional type 1 dendritic cells (cDC1s) capture antigens in peripheral tissues and migrate to draining lymph nodes (dLNs) to prime antigen-specific CD8 T cells. How tumor antigens are processed to activate CD8 T cell immunity is not well understood. In this work, we show that Ms4a7 is up-regulated in cDC1s after tumor antigen uptake or exposure to exogenous stimuli and is required for their cross-priming ability. Although Ms4a7−/− mice showed normal cDC1 development and turnover, they failed to prime antigen-specific CD8 T cells following infection or tumor development. In human cancers, MS4A7 was expressed in a subset of cDC1s, preferentially enriched in dLNs, and correlated with patient survival. Our findings suggest a critical role for Ms4a7 in cDC1-mediated cross-presentation and antitumor CD8 T cell responses.

**中文摘要译文：**
1型常规树突状细胞（cDC1s）在外周组织中捕获抗原，并迁移至引流淋巴结（dLNs）以启动抗原特异性CD8 T细胞。肿瘤抗原如何被加工以激活CD8 T细胞免疫的机制尚不完全清楚。本研究发现，在摄取肿瘤抗原或暴露于外源性刺激后，Ms4a7在cDC1s中表达上调，并且是其发挥交叉启动能力所必需的。尽管Ms4a7−/−小鼠的cDC1发育和更新正常，但它们在感染或肿瘤发生后未能启动抗原特异性CD8 T细胞。在人类癌症中，MS4A7在一部分cDC1s中表达，并优先富集于引流淋巴结，其表达水平与患者的生存率相关。我们的研究结果表明，Ms4a7在cDC1介导的交叉呈递及抗肿瘤CD8 T细胞应答中发挥着关键作用。

### 第二部分 AI 大师评价

本研究聚焦于探究Ms4a7分子在1型常规树突状细胞（cDC1s）介导的抗肿瘤免疫中的核心作用。研究通过基因敲除小鼠模型结合人类癌症数据分析，发现Ms4a7在cDC1s摄取肿瘤抗原后表达上调，并且是其进行交叉呈递以激活CD8 T细胞的关键。此项发现不仅揭示了调控抗肿瘤免疫启动的一个全新分子靶点，也为开发新型癌症免疫疗法（如治疗性疫苗）提供了重要的理论依据和潜在策略，其在人类癌症中的表达与患者生存率的相关性更凸显了其临床转化潜力。

---

## 37. 德州痴呆症研究人员为30亿美元新计划欢呼

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231993](https://pubmed.ncbi.nlm.nih.gov/41231993)
**期刊：** Science (New York, N.Y.)
**PMID：** 41231993
**DOI：** 10.1126/science.aed8418

### 第一部分 原文与翻译

**英文原标题：** Texas dementia researchers cheer $3 billion initiative.

**英文摘要原文：**
Voters approve new effort modeled after the state's long-running cancer research institute.

**中文摘要译文：**
选民批准了一项效仿该州长期运行的癌症研究所模式的新举措。

### 第二部分 AI 大师评价

本文报道了德克萨斯州一项具有里程碑意义的公共卫生举措：选民投票通过了一项总额达30亿美元的痴呆症研究计划。该计划借鉴了该州在癌症研究领域的长期成功模式，即由州政府资助的大型研究所。此项举措的批准不仅体现了公众对攻克痴呆症这一重大健康挑战的广泛共识，也预示着该领域将迎来大量的资金注入和研究机遇。虽然这并非一项原创性研究，但它揭示了科研资金政策的重要动向，其成功实施可能极大地推动痴呆症的基础研究和转化医学发展。

---

## 38. (-)-古枯宁A的三组分合成及其构效关系研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231967](https://pubmed.ncbi.nlm.nih.gov/41231967)
**期刊：** Science (New York, N.Y.)
**PMID：** 41231967
**DOI：** 10.1126/science.aea9310

### 第一部分 原文与翻译

**英文原标题：** Three-component assembly and structure-function relationships of (-)-gukulenin A.

**英文摘要原文：**
α-Tropolones comprise an unsaturated seven-membered ring bearing a hydroxyl substituent adjacent to a polarized carbon-oxygen π-bond. This polarization imparts a permanent molecular dipole and aromatic stabilization to the ring, resulting in unique physical properties, including affinity for divalent metals and ambiphilic reactivity. Among secondary metabolites that contain α-tropolones, the pseudodimeric isolate (-)-gukulenin A () stands out for its complexity and has shown promise in treating murine models of ovarian cancer. Here we describe an enantioselective synthesis of (-)-gukulenin A (). Key steps include a directed C-H arylation, a tandem Grob fragmentation-alkylation, an innovative synthesis of methyl tropolone ethers, a multicomponent cross-coupling, and a thermal carbonyl-ene reaction. Structure-function studies establish the dimeric tropolone and aldehyde substructures as drivers of cytotoxicity.

**中文摘要译文：**
α-环庚三烯酚酮包含一个不饱和的七元环，其上带有一个与极化的碳-氧π键相邻的羟基取代基。这种极化赋予了该环永久的分子偶极和芳香稳定性，从而产生了独特的物理性质，包括对二价金属的亲和力和双亲反应性。在含有α-环庚三烯酚酮的次级代谢产物中，假二聚体分离物(-)-古枯宁A以其复杂性而著称，并已在治疗卵巢癌小鼠模型中显示出应用前景。在此，我们报道了(-)-古枯宁A的对映选择性合成方法。关键步骤包括：导向的C-H键芳基化、串联的Grob断裂-烷基化、创新的甲基环庚三烯酚酮醚合成、多组分交叉偶联以及热羰基-烯反应。构效关系研究证实，二聚体环庚三烯酚酮和醛亚结构是其细胞毒性的驱动因素。

### 第二部分 AI 大师评价

本研究报道了一种复杂天然产物(-)-古枯宁A的对映选择性全合成路线，该分子在卵巢癌动物模型中展现出治疗潜力。研究团队巧妙地运用了包括C-H键活化、串联反应和多组分偶联在内的一系列现代有机合成策略，成功构建了目标分子。更为重要的是，通过构效关系分析，该研究明确了其二聚体环庚三烯酚酮和醛基部分是产生细胞毒性的关键结构。这项发表于《科学》杂志的成果不仅攻克了该分子的合成难题，也为其作为抗癌药物的进一步开发和优化提供了重要的理论依据和物质基础。

---

## 39. scMOVIR：一个针对人类病毒感染和免疫反应的单细胞多组学数据库

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231764](https://pubmed.ncbi.nlm.nih.gov/41231764)
**期刊：** Nucleic acids research
**PMID：** 41231764
**DOI：** 10.1093/nar/gkaf1153

### 第一部分 原文与翻译

**英文原标题：** scMOVIR: a single-cell multi-omics database for human viral infections and immune responses.

**英文摘要原文：**
Viral infections impose a substantial threat to human health, characterized by a wide range of pathogens, clinical manifestations, and complex immune responses. Single-cell multi-omics technologies have revolutionized the study of antiviral immunity by resolving cellular heterogeneity, transcriptional reprogramming, and clonal dynamics. However, no resource has yet comprehensively integrated such datasets in the context of viral infections. Here, we present scMOVIR, a single-cell multi-omics database for human viral infections and immune responses. The database systematically integrates transcriptomic, proteomic, and immune receptor repertoire profiles at single-cell resolution, compiling 8532 human samples across 114 viral species, subtypes, and strains. These datasets span 59 well-defined disease states, including acute and chronic infections, virus-associated malignancies, and immune-related disorders, and extend across >30 tissue types. In addition, these datasets incorporate vaccination cohorts, therapeutic interventions, and time-course models of infection. To ensure consistency and interoperability, all datasets undergo standardized preprocessing, including batch correction and unified cell-type annotation, with metadata harmonized using authoritative ontologies. scMOVIR provides user-friendly interfaces for dataset exploration and interactive visualization of cellular dynamics and molecular profiles, offering a high-resolution reference for investigating virus-host immune interactions and supporting antiviral research. The database is freely accessible at https://pgx.zju.edu.cn/scmovir.

**中文摘要译文：**
病毒感染对人类健康构成重大威胁，其特点是病原体种类繁多、临床表现各异以及免疫反应复杂。单细胞多组学技术通过解析细胞异质性、转录重编程和克隆动态，彻底改变了抗病毒免疫的研究。然而，目前尚无资源在病毒感染背景下对此类数据集进行全面整合。在此，我们推出了scMOVIR，一个关于人类病毒感染和免疫反应的单细胞多组学数据库。该数据库在单细胞分辨率下系统性地整合了转录组、蛋白质组和免疫受体库图谱，汇编了来自114种病毒（包括不同物种、亚型和毒株）的8532个人类样本。这些数据集涵盖了59种明确的疾病状态，包括急性和慢性感染、病毒相关恶性肿瘤以及免疫相关疾病，并横跨超过30种组织类型。此外，这些数据集还包含了疫苗接种队列、治疗干预和感染的时间进程模型。为确保一致性和互操作性，所有数据集都经过标准化的预处理，包括批次校正和统一的细胞类型注释，并使用权威的本体论对元数据进行协调。scMOVIR提供了用户友好的界面，用于数据集探索以及细胞动态和分子图谱的交互式可视化，为研究病毒-宿主免疫互作和支持抗病毒研究提供了一个高分辨率的参考。该数据库可在 https://pgx.zju.edu.cn/scmovir 免费访问。

### 第二部分 AI 大师评价

本研究构建并推出了scMOVIR，首个全面整合人类病毒感染相关单细胞多组学数据的数据库。该数据库通过系统性地汇集和标准化处理海量样本的转录组、蛋白质组及免疫受体库数据，填补了该领域的空白。scMOVIR不仅是一个强大的数据资源库，其友好的交互界面也为研究人员探索病毒-宿主相互作用提供了前所未有的便利。此项工作极具价值，将有力推动抗病毒免疫机制的深入研究，并可能加速新型疫苗和治疗策略的开发。

---

## 40. MASLD患者的纤维化、临床事件及死亡预测因素：来自全球MASLD研究的数据

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231627](https://pubmed.ncbi.nlm.nih.gov/41231627)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41231627
**DOI：** 10.1097/HEP.0000000000001617

### 第一部分 原文与翻译

**英文原标题：** Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study.

**英文摘要原文：**
BACKGROUND: Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of non-invasive markers (NITs) of fibrosis for adverse outcomes.

METHODS: The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and non-invasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed.

RESULTS: There were 17,792 MASLD patients. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p<0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events (p<0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all aHR>1.0, p<0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values.

CONCLUSIONS: In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with non-invasive tests.

**中文摘要译文：**
背景：晚期组织学纤维化是代谢功能障碍相关脂肪性肝病（MASLD）死亡率的主要预测因素。本研究旨在确定不同MASLD人群中晚期纤维化的临床决定因素，并评估纤维化无创标志物（NITs）对不良结局的预后价值。

方法：全球MASLD（G-MASLD）研究招募了经活检确诊、并具备临床、组织学及无创检测（NIT）数据的MASLD患者。本研究评估了与MASLD患者出现晚期组织学纤维化（F3-F4）及临床结局相关的因素。

结果：研究共纳入17,792名MASLD患者。35%的患者存在晚期纤维化（≥F3）。2型糖尿病（T2D）的患病率随纤维化分期的进展而逐步升高，从F0期的28%增至F4期的70%（趋势p<0.0001）。晚期纤维化的独立预测因素包括高龄、T2D和肥胖，但肥胖与晚期纤维化的关联因地区而异。在获得随访的患者中（平均随访6.6年），6.5%死亡，10.1%经历了临床事件。高龄、男性、T2D和肥胖是死亡率和临床事件的独立预测因素（p<0.05）。无论是通过组织学还是NITs定义的纤维化严重程度，均与更高的死亡风险和肝脏相关结局风险密切相关（所有aHR>1.0, p<0.001）。总体五年死亡率为2.1%，在肝硬化患者中升至8.3%，而在高风险NIT评分值的患者中则超过10%。

结论：在这个基于活检的大型全球MASLD队列中，晚期纤维化患病率高，且与T2D密切相关。组织学纤维化和NITs均为死亡率和临床结局的独立预测因素，这凸显了使用无创检测评估纤维化的预后价值。

### 第二部分 AI 大师评价

本研究基于一个大规模全球MASLD队列，旨在明确晚期纤维化的临床决定因素及其对临床结局的预测价值。其核心价值在于利用庞大的活检确诊病例数据，证实了高龄、2型糖尿病和肥胖是晚期纤维化的关键预测因子。研究不仅再次强调了纤维化分期对预后的决定性作用，更重要的是，它强有力地验证了无创诊断标志物（NITs）在预测死亡率和临床事件方面的有效性，为在全球范围内推广使用NITs进行风险分层管理提供了高级别证据。

---

## 41. 用于接受减重手术的肥胖个体中风险性代谢功能障碍相关脂肪性肝炎的无创评分模型的开发与验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231578](https://pubmed.ncbi.nlm.nih.gov/41231578)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41231578
**DOI：** 10.1097/HEP.0000000000001612

### 第一部分 原文与翻译

**英文原标题：** Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery.

**英文摘要原文：**
BACKGROUND: -At-risk metabolic dysfunction-associated steatohepatitis (MASH) elevates risks of liver-related and all-cause morbidity and mortality. We developed and validated a non-invasive score using routine clinical indicators to identity at-risk MASH in obesity.

METHODS: -Using data from 1,961 individuals across 5 independent bariatric cohorts with liver biopsy, we developed the predictive score in one derivation cohort (n=1095), performed internal validation (bootstrapping), and conducted external validation using the remaining four biopsy-confirmed cohorts (n=866). The score was also validated in the international overweight/obese cohorts from UK Biobank (n=15745) and NHANES database (n=1573). Predictive value for severe liver-related outcomes (SLROs, including cirrhosis, hepatocellular carcinoma, etc) was assessed in a UK Biobank subcohort (n=1955; median 13.7-year follow-up). Head-to-head comparisons with existing indices were performed.

RESULTS: -The predictive model, designated as FMO (Fibrotic/at-risk MASH in Obesity), incorporated aspartate aminotransferase, alanine aminotransferase, triglyceride, and high-density lipoprotein cholesterol. The FMO model demonstrated robust discrimination in derivation (AUROC=0.874, 95% CI 0.844-0.905) and nationwide external validation cohorts (AUROCs=0.803-0.874), and in global validation in both NHANES and UK Biobank (AUROCs=0.866 and 0.753, respectively). Longitudinal analysis confirmed SLROs prediction (Harrell's C- index=0.703). In the derivation cohort, the FMO model demonstrated optimal rule-out [cutoff 0.05, sensitivity ≥0.90, negative predictive value (NPV) 0.976] and rule-in [cutoff 0.22, specificity ≥0.90, positive predictive value (PPV) 0.481] performance. External validation showed NPVs of 0.907-1.00 and PPVs of 0.333-0.630. Comparative analyses revealed superior diagnostic performance of the FMO model versus some existing models.

CONCLUSION: -The FMO is an accurate and cost-effective non-invasive score for at-risk MASH identification in populations with obesity.

**中文摘要译文：**
背景：风险性代谢功能障碍相关脂肪性肝炎（MASH）会增加肝脏相关及全因发病率和死亡率的风险。我们利用常规临床指标，开发并验证了一种用于识别肥胖人群中风险性MASH的无创评分模型。

方法：我们使用来自5个独立的、经肝活检证实的减重手术队列中的1961名个体数据，在一个衍生队列（n=1095）中开发了该预测评分，通过自助法（bootstrapping）进行了内部验证，并利用其余四个经活检证实的队列（n=866）进行了外部验证。该评分还在来自英国生物银行（UK Biobank）的国际超重/肥胖队列（n=15745）和NHANES数据库（n=1573）中得到了验证。在一个英国生物银行的亚队列中（n=1955；中位随访13.7年），我们评估了该评分对严重肝脏相关结局（SLROs，包括肝硬化、肝细胞癌等）的预测价值。我们还将其与现有的其他指数进行了头对头比较。

结果：该预测模型被命名为FMO（肥胖症中的纤维化性/风险性MASH），其纳入了天冬氨酸氨基转移酶、丙氨酸氨基转移酶、甘油三酯和高密度脂蛋白胆固醇。FMO模型在衍生队列（AUROC=0.874, 95% CI 0.844-0.905）、全国性外部验证队列（AUROCs=0.803-0.874）以及在NHANES和英国生物银行的全球验证中（AUROCs分别为0.866和0.753）均表现出强大的区分能力。纵向分析证实了其对严重肝脏相关结局的预测能力（Harrell's C- index=0.703）。在衍生队列中，FMO模型展示了最佳的排除（截断值0.05，灵敏度≥0.90，阴性预测值(NPV) 0.976）和诊断（截断值0.22，特异度≥0.90，阳性预测值(PPV) 0.481）性能。外部验证显示，其阴性预测值范围为0.907-1.00，阳性预测值范围为0.333-0.630。对比分析显示，FMO模型的诊断性能优于部分现有模型。

结论：FMO评分是用于识别肥胖人群中风险性MASH的一种准确且具成本效益的无创工具。

### 第二部分 AI 大师评价

本研究旨在针对接受减重手术的肥胖人群，开发并验证一个用于识别高风险代谢功能障碍相关脂肪性肝炎（at-risk MASH）的无创评分模型（FMO）。该研究的突出之处在于其严谨的多中心、大规模队列设计，不仅包含了衍生和内部验证，还在多个独立的国际队列中进行了广泛的外部验证，并评估了其对长期严重肝脏结局的预测能力。研究成功构建了一个仅基于四项常规血液指标的FMO评分，该评分展现出优异的诊断区分度和高阴性预测值，在临床应用中可作为一种便捷、经济的筛查工具，有效识别低风险个体，从而可能减少不必要的侵入性肝活检。

---

## 42. 巨噬细胞代谢重编程：谷氨酰胺在β-连环蛋白突变型肝细胞癌中的挽救作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231538](https://pubmed.ncbi.nlm.nih.gov/41231538)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41231538
**DOI：** 10.1097/HEP.0000000000001619

### 第一部分 原文与翻译

**英文原标题：** Metabolic reprogramming in macrophages: A glutamine rescue in β-catenin mutant hepatocellular carcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究基于文献标题推断，旨在探讨巨噬细胞的代谢重编程，特别是在β-连环蛋白（β-catenin）突变型肝细胞癌（HCC）背景下，谷氨酰胺所扮演的关键角色。研究的核心发现可能揭示了谷氨酰胺能够“挽救”或恢复巨噬细胞在特定肿瘤微环境中的功能，从而可能抑制肿瘤进展。这项工作将肿瘤遗传学（β-catenin突变）、免疫细胞代谢（巨噬细胞）和肿瘤微环境联系起来，为靶向特定HCC亚型的代谢-免疫疗法提供了新的视角和潜在靶点，具有重要的科研价值和临床转化潜力。

---

## 43. 错配修复：癌症中一个动态且具有临床可操作性的弱点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40991396](https://pubmed.ncbi.nlm.nih.gov/40991396)
**期刊：** Cancer research
**PMID：** 40991396
**DOI：** 10.1158/0008-5472.CAN-25-2255

### 第一部分 原文与翻译

**英文原标题：** Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer.

**英文摘要原文：**
DNA mismatch repair (MMR) preserves genomic integrity by correcting replication errors. Deficiency in MMR results in microsatellite instability, increased tumor mutational burden, neoantigen generation, and activation of the immune response. In this review, we first outline how MMR loss promotes immune activation and responsiveness to immune checkpoint blockade (ICB), establishing MMR-deficient (MMRd) status as the first tumor-agnostic biomarker for ICB therapy. Subsequently, we summarize the compelling evidence that defines MMR status as a dynamic, context-dependent process influenced by environmental and therapeutic pressures, rather than a fixed, binary trait. Accordingly, we discuss the implications of the spatial and temporal heterogeneity of MMR status for both the diagnosis and treatment of cancer, the differential response of MMRd tumors to ICB, as well as the occasional benefits observed in MMR-proficient immune-cold cancers. We then explore strategies to exploit MMR dynamics and mimic MMRd-like phenotypes through alkylating agents, pharmacologic MMR inhibition, and stress-mediated modulation, with the aim of sensitizing refractory tumors to immunotherapy. Finally, we report emerging therapeutic opportunities in MMRd tumors, including Werner helicase inhibition, nonsense-mediated decay blockade, and neoantigen-targeted vaccines. Altogether, reframing MMR as a dynamic and targetable axis may broaden immunotherapy applicability and advance precision immune oncology across different tumor types.

**中文摘要译文：**
DNA错配修复（MMR）通过纠正复制错误来维持基因组的完整性。MMR功能缺陷会导致微卫星不稳定性、肿瘤突变负荷增加、新抗原生成以及免疫反应的激活。在这篇综述中，我们首先概述了MMR功能缺失如何促进免疫激活和对免疫检查点阻断（ICB）的应答，从而确立了MMR缺陷（MMRd）状态作为ICB治疗的首个泛癌种生物标志物。随后，我们总结了将MMR状态定义为一个受环境和治疗压力影响的、动态且依赖于具体情境的过程，而非一个固定的、二元性状的有力证据。因此，我们探讨了MMR状态时空异质性对癌症诊断与治疗的影响、MMRd肿瘤对ICB的差异性应答，以及在MMR功能完整的免疫冷肿瘤中有时观察到的益处。接着，我们探索了利用MMR动态特性并通过烷化剂、MMR的药物性抑制以及应激介导的调节来模拟MMRd样表型的策略，旨在使难治性肿瘤对免疫治疗敏感。最后，我们报告了MMRd肿瘤中新兴的治疗机会，包括Werner解旋酶抑制、无义介导的降解阻断以及靶向新抗原的疫苗。总而言之，将MMR重塑为一个动态且可靶向的轴心，可能会拓宽免疫治疗的适用性，并推动不同肿瘤类型中精准免疫肿瘤学的发展。

### 第二部分 AI 大师评价

该综述深刻地将DNA错配修复（MMR）从一个静态的生物标志物重塑为一个动态且可靶向的癌症弱点。文章系统性地总结了MMR状态的动态变化及其对免疫治疗应答的影响，并前瞻性地探讨了通过模拟MMR缺陷状态来增敏难治性肿瘤的创新策略。此文不仅为理解肿瘤免疫微环境的复杂性提供了新视角，也为拓宽免疫检查点抑制剂的临床应用和开发精准联合疗法指明了重要方向，对肿瘤免疫研究和临床实践具有重要的指导价值。

---

## 44. SPP1+中性粒细胞介导BAP1失活肿瘤对免疫检查点阻断的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40939189](https://pubmed.ncbi.nlm.nih.gov/40939189)
**期刊：** Cancer research
**PMID：** 40939189
**DOI：** 10.1158/0008-5472.CAN-24-4962

### 第一部分 原文与翻译

**英文原标题：** SPP1+ Neutrophils Mediate Resistance to Immune Checkpoint Blockade in BAP1-Inactivated Tumors.

**英文摘要原文：**
UNLABELLED: BAP1 inactivation, observed across multiple human cancers, is linked to immune checkpoint blockade (ICB) resistance and adverse clinical outcomes. The mechanisms underlying BAP1-associated ICB sensitivity could provide potential targets to enhance ICB efficacy. In this study, we showed that BAP1 inactivation fosters an immunosuppressive tumor microenvironment, marked by increased infiltration of M2-like macrophages and neutrophils. Single-cell transcriptomic analysis revealed an expansion of SPP1+ neutrophils in ICB-treated, BAP1-inactivated tumors. These SPP1+ neutrophils displayed a protumorigenic phenotype and conferred resistance to anti-PD-1 therapy by engaging with cytotoxic T cells via PD-1/PD-L1 signaling. Notably, depletion of neutrophils, but not macrophages, restored sensitivity to ICB in BAP1-inactivated tumors. Mechanistically, BAP1 loss significantly increased C-C motif chemokine ligand 2 (CCL2) secretion, driving neutrophil SPP1+ polarization, delaying neutrophil apoptosis, and promoting ICB resistance. This resistance could be significantly mitigated by targeting the CCL2-C-C chemokine receptor type 2 (CCR2) axis. These results underscore the role of BAP1 in modulating the immune landscape and suggest that targeting CCL2-CCR2-mediated neutrophil polarization may overcome ICB resistance in BAP1-inactivated tumors.

SIGNIFICANCE: BAP1 inactivation induces immunotherapy resistance and engenders an immunosuppressive microenvironment by enhancing CCL2 secretion and SPP1+ neutrophil polarization, which can be circumvented with CCL2-CCR2 inhibition to restore immune checkpoint blockade sensitivity.

**中文摘要译文：**
摘要：BAP1失活存在于多种人类癌症中，与免疫检查点阻断（ICB）耐药和不良临床结局相关。揭示BAP1相关的ICB敏感性背后的机制可能为提高ICB疗效提供潜在靶点。在本研究中，我们发现BAP1失活会促进一个以M2样巨噬细胞和中性粒细胞浸润增加为特征的免疫抑制性肿瘤微环境。单细胞转录组学分析显示，在接受ICB治疗的BAP1失活肿瘤中，SPP1+中性粒细胞数量出现扩增。这些SPP1+中性粒细胞表现出促肿瘤表型，并通过PD-1/PD-L1信号通路与细胞毒性T细胞相互作用，从而介导了对PD-1抑制剂治疗的耐药性。值得注意的是，在BAP1失活的肿瘤中，清除中性粒细胞（而非巨噬细胞）能够恢复对ICB的敏感性。从机制上讲，BAP1的缺失显著增加了C-C基序趋化因子配体2（CCL2）的分泌，从而驱动中性粒细胞向SPP1+表型极化，延缓其凋亡，并促进ICB耐药。通过靶向CCL2-C-C趋化因子受体2型（CCR2）轴，可以显著减弱这种耐药性。这些结果强调了BAP1在调节免疫微环境中的作用，并提示靶向CCL2-CCR2介导的中性粒细胞极化可能是克服BAP1失活肿瘤ICB耐药的一种策略。

研究意义：BAP1失活通过增强CCL2分泌和SPP1+中性粒细胞极化，诱导了免疫治疗耐药并营造了免疫抑制微环境，而通过抑制CCL2-CCR2轴可以逆转这一过程，恢复免疫检查点阻断的敏感性。

### 第二部分 AI 大师评价

本研究旨在阐明BAP1失活导致肿瘤对免疫检查点阻断（ICB）产生耐药性的具体机制。研究综合运用单细胞转录组学等前沿技术，关键性地发现BAP1失活通过上调CCL2分泌，驱动了具有免疫抑制功能的SPP1+中性粒细胞在肿瘤微环境中的富集与极化，进而介导了ICB耐药。该研究不仅深刻揭示了BAP1在肿瘤免疫调控中的新作用，更重要的是，其提出的靶向CCL2-CCR2轴以逆转耐药的策略，为携带BAP1失活突变的癌症患者提供了一种极具潜力的联合治疗新思路，具有重要的临床转化价值。

---

## 45. 卡博替尼联合阿替利珠单抗治疗晚期进展性内分泌恶性肿瘤：一项多队列、篮子II期试验 (CABATEN/GETNE-T1914)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40938918](https://pubmed.ncbi.nlm.nih.gov/40938918)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40938918
**DOI：** 10.1158/1078-0432.CCR-25-2143

### 第一部分 原文与翻译

**英文原标题：** Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

**英文摘要原文：**
PURPOSE: Multikinase inhibitors have shown efficacy in endocrine neoplasms, and synergism with immune checkpoint inhibitors has been noted in other tumors.

PATIENTS AND METHODS: This is a prospective, multicenter, open-label, Simon two-stage optimal design, phase II study including patients with advanced and refractory endocrine and neuroendocrine neoplasms in six cohorts: lung well-differentiated neuroendocrine tumors, anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PPGL), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET), and grade 3 extrapulmonary neuroendocrine neoplasms. Patients received atezolizumab 1,200 mg intravenously every 3 weeks plus cabozantinib 40 mg/day orally until disease progression or unacceptable toxicity. The primary objective was the overall response rate (ORR) by RECIST 1.1.

RESULTS: From October 2020 to December 2022, 93 patients were included. The ORR was 14.3% [95% confidence interval (CI), 1.8-42.8] in ATC (N = 14); 8.3% (95% CI, 1.0-27.0) in ACC (N = 24); 15.4% (95% CI, 1.9-45.5) in PPGL (N = 13), and 16.7% (95% CI, 4.7-37.4) in GEP-NET (N = 24). Lung well-differentiated neuroendocrine tumors and grade 3 extrapulmonary neuroendocrine neoplasms had no responses. The duration of response was 20.4 months in ATC, 13.1 months in ACC, 12.2 months in PPGL, and 15.8 months in GEP-NET. Survival rates at 12 months in ATC and ACC were 47.6% and 47.6%, respectively. No unexpected toxicity was observed.

CONCLUSIONS: Cabozantinib and atezolizumab were safely administered and showed promising ORR, and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation.

**中文摘要译文：**
目的：多激酶抑制剂已在内分泌肿瘤中显示出疗效，并且在其他肿瘤中也观察到其与免疫检查点抑制剂的协同作用。

患者与方法：这是一项前瞻性、多中心、开放标签、采用Simon两阶段优化设计的II期研究，纳入了患有晚期和难治性内分泌及神经内分泌肿瘤的患者，分为六个队列：肺高分化神经内分泌瘤、甲状腺未分化癌（ATC）、肾上腺皮质癌（ACC）、嗜铬细胞瘤/副神经节瘤（PPGL）、高分化胃肠胰神经内分泌瘤（GEP-NET）以及3级肺外神经内分泌肿瘤。患者接受每3周一次1200毫克阿替利珠单抗静脉注射，联合每日口服40毫克卡博替尼，直至疾病进展或出现不可接受的毒性。主要研究终点是根据RECIST 1.1标准评估的总缓解率（ORR）。

结果：自2020年10月至2022年12月，共纳入93名患者。在甲状腺未分化癌（ATC）患者（N=14）中，ORR为14.3% [95%置信区间（CI），1.8-42.8]；在肾上腺皮质癌（ACC）患者（N=24）中为8.3%（95% CI, 1.0-27.0）；在嗜铬细胞瘤/副神经节瘤（PPGL）患者（N=13）中为15.4%（95% CI, 1.9-45.5）；在胃肠胰神经内分泌瘤（GEP-NET）患者（N=24）中为16.7%（95% CI, 4.7-37.4）。肺高分化神经内分泌瘤和3级肺外神经内分泌肿瘤队列未观察到缓解。在ATC患者中，缓解持续时间为20.4个月，ACC患者为13.1个月，PPGL患者为12.2个月，GEP-NET患者为15.8个月。ATC和ACC患者的12个月生存率分别为47.6%和47.6%。未观察到非预期的毒性反应。

结论：卡博替尼与阿替利珠单抗的联合用药安全性良好，并在经过多线治疗的侵袭性ACC和ATC患者中显示出有前景的ORR和初步的长期生存率，值得进一步研究。

### 第二部分 AI 大师评价

该研究通过一项II期篮子试验，旨在评估卡博替尼联合阿替利珠单抗治疗多种晚期进展性内分泌系统恶性肿瘤的疗效与安全性。其关键发现是在侵袭性强且经多线治疗的肾上腺皮质癌（ACC）和甲状腺未分化癌（ATC）等罕见瘤种中观察到了有临床意义的客观缓解率和令人鼓舞的长期生存数据，且安全性可控。这项研究的创新性在于将靶向与免疫疗法结合，并应用于一组异质性高、治疗选择有限的肿瘤类型，其结果为这些难治性癌症提供了重要的治疗新证据，预示了该联合方案在特定亚组中的应用潜力，值得开展更大规模的试验进行验证。

---

## 46. 在三阴性乳腺癌中，于新辅助化疗联合免疫治疗前设置阿替利珠单抗单药治疗窗口期的研究——neoMono试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40932365](https://pubmed.ncbi.nlm.nih.gov/40932365)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40932365
**DOI：** 10.1158/1078-0432.CCR-25-1288

### 第一部分 原文与翻译

**英文原标题：** Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial.

**英文摘要原文：**
PURPOSE: Exploratory data suggest a benefit of an immune checkpoint inhibitor (ICI) monotherapy window in early triple-negative breast cancer (TNBC). The neoMono trial prospectively investigated whether the addition of an atezolizumab monotherapy window before neoadjuvant atezolizumab and chemotherapy improves pathologic complete remission (pCR) rates in early TNBC.

PATIENTS AND METHODS: neoMono is a phase 2 randomized multicenter trial that recruited patients with primary TNBC larger than 10 mm. Neoadjuvant treatment in both arms consisted of neoadjuvant atezolizumab and chemotherapy, with treatment in arm A preceded by atezolizumab monotherapy 2 weeks before combination therapy. This study used a Bayesian trial design.

RESULTS: A total of 359 patients were included. Overall, pCR rates in study arms A and B were similar (intention-to-treat population: 65.7% and 69.0%, respectively). In an exploratory analysis, pCR rates in PD-L1-positive tumors were 91.5% in arm A and 82.2% in arm B. The corresponding pCR rates in the PD-L1-negative group were 56.1% in arm A and 64.5% in arm B. In patients with low-risk TNBC (cT1c and cN0), pCR rates in the PD-L1-positive group were 100.0% in arm A and 90.0% in arm B, and the corresponding pCR rates in the PD-L1 (immune cell)-negative group were 65.9% and 76.3%, respectively.

CONCLUSIONS: The neoMono trial demonstrated the highest pCR rates reported in a phase II/III trial in TNBC, particularly in the case of PD-L1 positivity. Although no significant impact of an ICI monotherapy window on the pCR rate in the unselected intention-to-treat population could be demonstrated, our data reinforce the use of combinations of neoadjuvant chemotherapy and ICI in this indication.

**中文摘要译文：**
目的：探索性数据表明，在早期三阴性乳腺癌（TNBC）中使用免疫检查点抑制剂（ICI）单药治疗窗口期可能带来获益。neoMono试验前瞻性地研究了在新辅助阿替利珠单抗联合化疗之前，增加一个阿替利珠单抗单药治疗窗口期是否能提高早期TNBC的病理学完全缓解（pCR）率。

患者与方法：neoMono是一项2期随机多中心试验，招募了原发性TNBC大于10毫米的患者。两组的新辅助治疗均包括新辅助阿替利珠单抗和化疗，其中A组在联合治疗前接受为期2周的阿替利珠单抗单药治疗。本研究采用了贝叶斯试验设计。

结果：共纳入359名患者。总体而言，研究A组和B组的pCR率相似（意向治疗人群：分别为65.7%和69.0%）。在一项探索性分析中，PD-L1阳性肿瘤患者的pCR率在A组为91.5%，B组为82.2%。相应的，PD-L1阴性组的pCR率在A组为56.1%，B组为64.5%。在低风险TNBC患者（cT1c和cN0）中，PD-L1阳性组的pCR率在A组为100.0%，B组为90.0%；相应的，PD-L1（免疫细胞）阴性组的pCR率分别为65.9%和76.3%。

结论：neoMono试验展示了在TNBC的II/III期试验中所报道的最高pCR率，尤其是在PD-L1阳性的情况下。尽管未能证实在未经筛选的意向治疗人群中，ICI单药治疗窗口期对pCR率有显著影响，但我们的数据加强了在该适应症中使用新辅助化疗与ICI联合治疗的依据。

### 第二部分 AI 大师评价

该研究（neoMono试验）通过一项II期随机多中心试验，创新性地探讨了在标准新辅助免疫联合化疗前，设置一个阿替利珠单抗单药治疗窗口期，能否进一步提升早期三阴性乳腺癌（TNBC）的病理学完全缓解（pCR）率。尽管研究未能在总人群中证实该窗口期的显著获益，但其报告的pCR率，尤其是在PD-L1阳性亚组中（在A组中达到91.5%），是迄今在TNBC II/III期试验中报道的最高水平。此项研究不仅有力地支持了新辅助化疗联合免疫检查点抑制剂作为TNBC标准治疗的地位，也为未来探索优化PD-L1阳性患者治疗策略提供了宝贵的探索性数据。

---

## 47. 溶瘤病毒CVA21联合派姆单抗对晚期非小细胞肺癌免疫原性及肿瘤微环境的影响：一项I/II期试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40932352](https://pubmed.ncbi.nlm.nih.gov/40932352)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40932352
**DOI：** 10.1158/1078-0432.CCR-25-1449

### 第一部分 原文与翻译

**英文原标题：** Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

**英文摘要原文：**
PURPOSE: Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non-small cell lung cancers. There is an unmet need to improve outcomes for patients with this condition. Oncolytic viruses represent an attractive treatment approach because of their dual activity in inducing tumor cell lysis directly and potentially augmenting antitumor immunity. In this study, we present the safety, efficacy, and translational findings from a phase I/II single-arm trial utilizing CVA21, an oncolytic coxsackievirus, in combination with pembrolizumab in patients with advanced pretreated non-small cell lung cancers.

PATIENTS AND METHODS: We performed paired pre- and posttreatment biopsies in 10 patients who received intravenous CVA21 and pembrolizumab, eight of whom had prior treatment with immune checkpoint inhibitor therapy. Whole-genome sequencing and spatial proteomics were performed to comprehensively characterize the response to CVA21.

RESULTS: Combination CVA21/pembrolizumab (anti-PD-1) therapy was well tolerated with no serious treatment-related adverse events. Partial responses were seen in two patients with prior acquired anti-PD-1 resistance and disease stabilization in six patients, giving a clinical benefit rate of 80%. High baseline tumor mutational burden and PD-L1 expression were observed in patients with better response to treatment. Interestingly, an increase in antigen presentation and CD8+ T-cell infiltration was observed on-treatment compared with baseline in patients with better progression-free survival.

CONCLUSIONS: This study demonstrates the potential of CVA21 to modulate the immunogenicity of tumor cells and remodel the tumor microenvironment, providing insights for patient selection for trials involving novel immunotherapeutic approaches.

**中文摘要译文：**
目的：大多数晚期非小细胞肺癌患者会对免疫检查点抑制剂产生获得性或原发性耐药。改善这类患者的预后，是当前一个亟待满足的临床需求。溶瘤病毒因其既能直接诱导肿瘤细胞裂解，又能潜在增强抗肿瘤免疫的双重活性，成为一种极具吸引力的治疗策略。在本研究中，我们报告了一项I/II期单臂试验的安全性、有效性及转化研究结果，该试验采用溶瘤柯萨奇病毒CVA21联合派姆单抗治疗经治的晚期非小细胞肺癌患者。

患者与方法：我们对10名接受CVA21静脉注射联合派姆单抗治疗的患者进行了治疗前后的配对活检，其中8名患者曾接受过免疫检查点抑制剂治疗。我们通过全基因组测序和空间蛋白质组学全面表征了患者对CVA21的响应。

结果：CVA21联合派姆单抗（抗PD-1）治疗的耐受性良好，未发生与治疗相关的严重不良事件。在既往对PD-1抑制剂产生获得性耐药的患者中，观察到2例部分缓解和6例疾病稳定，临床获益率达80%。治疗反应较好的患者基线时表现出较高的肿瘤突变负荷和PD-L1表达水平。有趣的是，与基线相比，无进展生存期较长的患者在治疗期间表现出抗原呈递增强和CD8+ T细胞浸润增加。

结论：本研究证实了CVA21在调节肿瘤细胞免疫原性和重塑肿瘤微环境方面的潜力，为涉及新型免疫治疗方法的临床试验筛选患者提供了见解。

### 第二部分 AI 大师评价

本研究旨在评估溶瘤病毒CVA21联合派姆单抗治疗免疫检查点抑制剂耐药的晚期非小细胞肺癌患者的安全性与有效性。通过一项小样本I/II期临床试验，并结合治疗前后活检样本的深度分析，研究团队发现该联合疗法不仅耐受性良好，且在耐药患者中仍能实现高达80%的临床获益率。其核心价值在于揭示了溶瘤病毒能够重塑“冷”肿瘤微环境，增强肿瘤免疫原性和CD8+ T细胞浸润，从而可能逆转免疫治疗耐药，为开发新型联合免疫策略提供了重要证据和生物标志物线索。

---

## 48. Tarlatamab的暴露-疗效与暴露-安全性关系研究：为小细胞肺癌患者的剂量选择提供依据

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40928991](https://pubmed.ncbi.nlm.nih.gov/40928991)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40928991
**DOI：** 10.1158/1078-0432.CCR-25-2134

### 第一部分 原文与翻译

**英文原标题：** Tarlatamab Exposure-Efficacy and Exposure-Safety Relationships to Inform Dose Selection in Patients with Small Cell Lung Cancer.

**英文摘要原文：**
PURPOSE: Tarlatamab is a first-in-class, half-life extended bispecific T-cell engager immunotherapy targeting delta-like ligand 3, currently approved for the treatment of adult patients with small cell lung cancer with disease progression on or after platinum-based chemotherapy. In this study, we report tarlatamab exposure-response relationships to inform dose selection in patients with small cell lung cancer.

PATIENTS AND METHODS: Pharmacokinetic data were correlated with therapeutic effect (exposure-response analyses) for efficacy and safety measures using pooled data from the DeLLphi-300 and DeLLphi-301 studies. Efficacy measures included objective response rate, disease control rate, best change from baseline in tumor size, progression-free survival, and overall survival. Safety events included treatment-emergent adverse events (TEAE), treatment-related adverse events, and TEAE of interest, including cytokine release syndrome, neutropenia, and neurologic toxicity such as immune effector cell-associated neurotoxicity syndrome. Effects of patient-specific factors were also assessed. Doses ranging from 0.003 to 100 mg every 2 weeks and 200 mg every 3 weeks were explored.

RESULTS: Significant positive exposure-response relationships were established for all evaluated efficacy measures. Near-maximal efficacy was reached at exposures associated with the clinical regimen of 10 mg every 2 weeks. No relationships with exposure were identified for the following grade ≥3 events: TEAE, treatment-related adverse events, cytokine release syndrome, and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. A shallow trend was observed for a higher percentage of patients experiencing grade ≥3 neutropenia with higher exposures.

CONCLUSIONS: This analysis supports a 10-mg every-2-weeks regimen and that no dose adjustment is necessary based on age, race, body weight, immunogenicity, number of prior therapies, or disease burden.

**中文摘要译文：**
目的：Tarlatamab是一款首创的、半衰期延长的双特异性T细胞衔接免疫疗法，靶向δ样配体3，目前已被批准用于治疗接受铂类化疗期间或之后出现疾病进展的成人小细胞肺癌患者。本研究旨在报告tarlatamab的暴露-反应关系，为小细胞肺癌患者的剂量选择提供信息。

患者与方法：本研究使用了来自DeLLphi-300和DeLLphi-301研究的汇总数据，将药代动力学数据与疗效和安全性指标的治疗效果（暴露-反应分析）进行关联。疗效指标包括客观缓解率、疾病控制率、肿瘤大小相较于基线的最佳变化、无进展生存期和总生存期。安全性事件包括治疗期间出现的不良事件（TEAE）、治疗相关不良事件以及关注的TEAE，包括细胞因子释放综合征、中性粒细胞减少症和神经系统毒性（如免疫效应细胞相关神经毒性综合征）。研究还评估了患者特异性因素的影响。探索的剂量范围为每2周0.003至100毫克以及每3周200毫克。

结果：所有评估的疗效指标均建立了显著的正向暴露-反应关系。在与每2周10毫克的临床方案相关的暴露水平下，疗效接近最大化。对于以下≥3级事件，未发现其与暴露水平存在关系：TEAE、治疗相关不良事件、细胞因子释放综合征和包括免疫效应细胞相关神经毒性综合征在内的神经系统毒性。观察到一个微弱的趋势，即随着暴露水平的升高，经历≥3级中性粒细胞减少症的患者比例更高。

结论：本分析支持采用每2周10毫克的给药方案，并且无需根据年龄、种族、体重、免疫原性、既往治疗线数或疾病负荷进行剂量调整。

### 第二部分 AI 大师评价

本研究通过对两项关键临床试验数据的汇总分析，系统探讨了首创药物Tarlatamab在小细胞肺癌患者中的暴露-疗效与暴露-安全性关系。其核心价值在于为Tarlatamab的临床推荐剂量（每2周10mg）提供了坚实的药代动力学与药效学证据。研究明确指出，此剂量在达到近乎最大疗效的同时，并未显著增加多数严重不良事件的风险，且无需根据患者个体差异调整剂量，这极大地简化了临床实践，对指导该创新疗法的精准应用具有重要意义。

---

## 49. CD27激动剂抗体通过瘤内刺激在B细胞恶性肿瘤中介导临床反应：多中心RiVa试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40920567](https://pubmed.ncbi.nlm.nih.gov/40920567)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40920567
**DOI：** 10.1158/1078-0432.CCR-25-2029

### 第一部分 原文与翻译

**英文原标题：** CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

**英文摘要原文：**
PURPOSE: Varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show that agonistic CD27 antibodies can activate intratumoral T cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e., rituximab, in B-cell lymphoma. This clinical trial evaluated the safety and efficacy of rituximab and varlilumab in patients with previously treated B-cell non-Hodgkin lymphoma.

PATIENTS AND METHODS: This multicenter phase IIa trial recruited patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma. Patients were randomized to arm A or B. All patients received rituximab on day 1 of cycles 1 to 6 and varlilumab on day 2 (arm A) or day 8 (arm B) of cycle 1 and day 2 of cycles 3 and 5. Tumor biopsies were collected before treatment and on-treatment (after varlilumab in arm A and before varlilumab in arm B). The primary objective was to assess safety and antitumor activity.

RESULTS: Twenty-seven participants were evaluable, with modest overall response and disease control rates of 15.4% (4/27) and 38.8% (8/27), respectively. Intratumoral bulk RNA sequencing analysis demonstrated that adding varlilumab to rituximab enhanced CD4+ T-cell infiltration and increased T- and innate-cell signatures; inflamed tumor signatures were observed before treatment in responders. Single-cell analysis further showed that higher levels of CD27-expressing T and NK cells, along with activated γδ T-cell signatures, were associated with response, whereas CD27-expressing B cells correlated with nonresponse.

CONCLUSIONS: Rituximab and varlilumab show modest activity. However, CD27 agonist antibodies may elicit meaningful antitumor responses when tumors express sufficient intratumoral targets and exhibit existing immune priming.

**中文摘要译文：**
目的：Varlilumab是一种CD27激动剂抗体，可提供T细胞共刺激。临床前研究表明，在B细胞淋巴瘤中，激动性CD27抗体可激活瘤内T细胞释放趋化因子和细胞因子，从而增强由CD20抗体（即利妥昔单抗）诱导的巨噬细胞依赖性肿瘤杀伤作用。本临床试验旨在评估利妥昔单抗和varlilumab在既往接受过治疗的B细胞非霍奇金淋巴瘤患者中的安全性和有效性。

患者与方法：这项多中心IIa期试验招募了复发或难治性CD20+ B细胞非霍奇金淋巴瘤患者。患者被随机分配至A组或B组。所有患者在第1至第6个周期的第1天接受利妥昔单抗治疗，并在第1个周期的第2天（A组）或第8天（B组）以及第3和第5个周期的第2天接受varlilumab治疗。在治疗前和治疗期间（A组在varlilumab用药后，B组在varlilumab用药前）收集了肿瘤活检样本。主要研究目标是评估安全性和抗肿瘤活性。

结果：共有27名参与者可供评估，其总体缓解率和疾病控制率分别为15.4%（4/27）和38.8%（8/27），效果中等。瘤内批量RNA测序分析表明，在利妥昔单抗基础上加用varlilumab可增强CD4+ T细胞浸润并增加T细胞和固有免疫细胞特征；在治疗前，应答者中观察到炎性肿瘤特征。单细胞分析进一步显示，较高水平的表达CD27的T细胞和NK细胞，以及活化的γδ T细胞特征与应答相关，而表达CD27的B细胞则与无应答相关。

结论：利妥昔单抗和varlilumab联合治疗显示出中等活性。然而，当肿瘤表达足够的瘤内靶点并表现出预存的免疫启动状态时，CD27激动剂抗体可能引发有意义的抗肿瘤反应。

### 第二部分 AI 大师评价

该研究旨在评估CD27激动剂Varlilumab联合利妥昔单抗治疗B细胞非霍奇金淋巴瘤的疗效与安全性。通过一项IIa期临床试验结合瘤内转录组学分析，研究发现该联合方案临床活性中等。其核心价值在于揭示了疗效的潜在生物标志物：治疗前的炎性肿瘤特征及高水平的CD27+ T/NK细胞与更优的临床反应相关。尽管临床结果有限，但本研究为未来优化CD27激动剂的临床应用和筛选优势人群提供了重要的分子生物学依据。

---

## 50. 结合前沿分析的宽场光学氧化还原成像技术能够评估患者来源癌症类器官的治疗反应和异质性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40920506](https://pubmed.ncbi.nlm.nih.gov/40920506)
**期刊：** Cancer research
**PMID：** 40920506
**DOI：** 10.1158/0008-5472.CAN-24-4958

### 第一部分 原文与翻译

**英文原标题：** Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.

**英文摘要原文：**
UNLABELLED: Patient-derived cancer organoids (PDCO) are a valuable model to recapitulate human disease in culture, with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Label-free imaging methods are a promising tool to measure organoid-level heterogeneity and rapidly screen drug responses in PDCOs. This study aimed to assess and predict PDCO response to treatments based on mutational profiles using label-free wide-field optical redox imaging (WF ORI). WF ORI provided organoid-level measurements of treatment response without labels or additional reagents by measuring the autofluorescence intensity of the metabolic coenzymes NAD(P)H and FAD, and the optical redox ratio, defined as the fluorescence intensity of [NAD(P)H/NAD(P)H + FAD], was used to measure the oxidation-reduction state of PDCOs. Development of leading-edge analysis tools helped maximize the sensitivity and reproducibility of treatment response measurements using WF ORI in colorectal cancer PDCOs. Leading-edge analysis improved sensitivity to redox changes in treated PDCOs. Additionally, WF ORI resolved FOLFOX (5-fluorouracil + oxaliplatin) treatment effects across all PDCOs better than two-photon ORI, with an approximately threefold increase in effect size. WF ORI distinguished metabolic differences based on driver mutations in colorectal cancer PDCOs, differentiating between KRAS + PIK3CA double-mutant PDCOs and wild-type PDCOs with 80% accuracy and identified treatment-resistant mutations in mixed PDCO cultures. Overall, WF ORI enables rapid, sensitive, and reproducible measurements of treatment response and heterogeneity in colorectal PDCOs that will affect patient management, clinical trials, and preclinical drug development.

SIGNIFICANCE: Label-free wide-field optical redox imaging is an accessible tool for monitoring changes in metabolism in patient-derived cancer organoids to reproducibly assess treatment response and heterogeneity in clinically relevant treatment studies.

**中文摘要译文：**
患者来源的癌症类器官（PDCO）是在培养中重现人类疾病的一种宝贵模型，对药物开发具有重要意义。然而，目前用于快速、可重复地评估PDCOs的方法有限。无标记成像方法是一种有前途的工具，可用于测量类器官水平的异质性并快速筛选PDCOs中的药物反应。本研究旨在利用无标记宽场光学氧化还原成像（WF ORI），根据突变谱评估和预测PDCO对治疗的反应。WF ORI通过测量代谢辅酶NAD(P)H和FAD的自发荧光强度，提供无标记或无需额外试剂的类器官水平治疗反应测量；并利用定义为[NAD(P)H/NAD(P)H + FAD]荧光强度的光学氧化还原比率，来衡量PDCOs的氧化还原状态。前沿分析工具的开发有助于最大限度地提高利用WF ORI在结直肠癌PDCOs中测量治疗反应的灵敏度和可重复性。前沿分析提高了对经治疗的PDCOs中氧化还原变化的敏感性。此外，与双光子ORI相比，WF ORI能更好地解析所有PDCOs中FOLFOX（5-氟尿嘧啶+奥沙利铂）的治疗效果，其效应量增加了约三倍。WF ORI能够根据结直肠癌PDCOs中的驱动突变区分代谢差异，以80%的准确率区分KRAS + PIK3CA双突变PDCOs和野生型PDCOs，并在混合PDCO培养物中识别出耐药突变。总体而言，WF ORI能够对结直肠癌PDCOs的治疗反应和异质性进行快速、灵敏且可重复的测量，这将影响患者管理、临床试验和临床前药物开发。

意义：无标记宽场光学氧化还原成像是一种易于获取的工具，用于监测患者来源癌症类器官的代谢变化，从而在临床相关的治疗研究中可重复地评估治疗反应和异质性。

### 第二部分 AI 大师评价

本研究旨在验证一种名为宽场光学氧化还原成像（WF ORI）的无标记技术，用于快速、灵敏地评估患者来源癌症类器官（PDCOs）的治疗反应与异质性。其核心创新在于将WF ORI与新颖的“前沿分析”算法相结合，通过监测细胞代谢辅酶的自发荧光来精确量化类器官的氧化还原状态。研究关键发现，该方法在评估化疗效果上优于传统成像技术，并能根据驱动基因突变（如KRAS/PIK3CA）高精度区分不同类器官的代谢表型，为精准肿瘤学提供了一个强大的高通量筛选平台，具有加速个性化治疗方案制定和新药研发的巨大潜力。

---

## 51. 高尔基体浓缩通过激活YAP1促进胃癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40920502](https://pubmed.ncbi.nlm.nih.gov/40920502)
**期刊：** Cancer research
**PMID：** 40920502
**DOI：** 10.1158/0008-5472.CAN-24-3920

### 第一部分 原文与翻译

**英文原标题：** Condensation of the Golgi Apparatus Activates YAP1 to Promote Gastric Cancer Progression.

**英文摘要原文：**
UNLABELLED: Alterations in the structure of the Golgi apparatus play a pivotal role in cancer progression and invasion. A better understanding of how Golgi morphology regulates the metastatic potential of cancer cells could help identify potential treatment strategies. In this study, we investigated how specific structural variations in the Golgi, particularly fragmentation and condensation, influence the malignancy of gastric cancer using human cell lines, xenograft mouse models, and human patient tissue samples. Gastric cancer cells with condensed Golgi structures exhibited increased proliferation and migration. Mechanistic analyses indicated that Golgi condensation-associated malignancy was driven by enhanced formation of Golgi-derived microtubules, elevated vesicular trafficking, and augmented nuclear translocation of YAP1, a key transcriptional regulator of cell proliferation and tumorigenesis. Importantly, treatment with an agent that induces Golgi fragmentation significantly suppressed tumor growth in a xenograft mouse model. Furthermore, signet-ring cell carcinoma, an aggressive subtype of diffuse gastric cancer, exhibited a stronger inverse correlation between YAP1 activation and the Golgi area than both intestinal-type and non-signet ring cell carcinoma. These findings underscore the critical role of Golgi apparatus dynamics in oncogenic signaling pathways and reveal therapeutic targets in gastric cancer.

SIGNIFICANCE: Golgi condensation facilitates YAP1-mediated oncogenic progression in gastric cancer, highlighting Golgi structural modulation as a promising therapeutic strategy to inhibit malignant signaling and cellular dissemination.

**中文摘要译文：**
高尔基体的结构改变在癌症的进展和侵袭中扮演着关键角色。更深入地理解高尔基体形态如何调控癌细胞的转移潜能，可能有助于发现潜在的治疗策略。在本研究中，我们利用人类细胞系、异种移植小鼠模型以及人类患者组织样本，探究了高尔基体的特定结构变异（特别是碎片化和浓缩）如何影响胃癌的恶性程度。具有浓缩高尔基体结构的胃癌细胞表现出增强的增殖和迁移能力。机制分析表明，与高尔基体浓缩相关的恶性行为是由高尔基体来源的微管形成增强、囊泡运输增加以及YAP1（一种调控细胞增殖和肿瘤发生的关键转录调节因子）核转位增多所驱动的。重要的是，在异种移植小鼠模型中，使用一种诱导高尔基体碎片化的药物治疗，能显著抑制肿瘤生长。此外，与肠型胃癌和非印戒细胞癌相比，印戒细胞癌（一种侵袭性的弥漫性胃癌亚型）中YAP1的激活与高尔基体面积呈现出更强的负相关性。这些发现强调了高尔基体动力学在致癌信号通路中的关键作用，并揭示了胃癌的潜在治疗靶点。

重要性：高尔基体浓缩促进了YAP1介导的胃癌致癌进程，这凸显了调控高尔基体结构作为一种抑制恶性信号和细胞播散的有前景的治疗策略。

### 第二部分 AI 大师评价

本研究聚焦于高尔基体形态变化在胃癌进展中的作用，通过细胞、动物模型及临床样本等多维度证据，揭示了高尔基体浓缩是促进胃癌细胞增殖与迁移的关键因素。其核心创新在于，首次阐明了“高尔基体浓缩-微管网络-囊泡运输-YAP1核转位”这一完整的信号传导轴，为理解胃癌的恶性行为提供了新的细胞器层面机制。此发现不仅加深了对肿瘤生物学的理解，更提出靶向高尔基体结构作为一种潜在的胃癌治疗新策略，尤其对印戒细胞癌等侵袭性亚型具有重要临床启示。

---

## 52. 西曲替尼通过靶向TYRO3增强PD-1阻断在肝细胞癌中的抗肿瘤免疫应答

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40353734](https://pubmed.ncbi.nlm.nih.gov/40353734)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40353734
**DOI：** 10.1158/1078-0432.CCR-24-4338

### 第一部分 原文与翻译

**英文原标题：** Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.

**英文摘要原文：**
PURPOSE: Tyrosine kinase inhibitors combined with immune checkpoint blockades produce enhanced antitumor activity in the treatment of advanced hepatocellular carcinoma (HCC). Sitravatinib is a novel multitarget tyrosine kinase inhibitor that targets TYRO3, AXL, and MERTK receptors, c-MET, etc. This study aimed to investigate the antitumor efficacy and immunomodulatory activity of sitravatinib in HCC.

EXPERIMENTAL DESIGN: Human HCC cell lines and xenograft models were used to explore the antitumor activity of sitravatinib. Subcutaneous and orthotopic immunocompetent murine HCC models were used to assess the therapeutic efficacy of sitravatinib and PD-1 blockade combination therapy. Cocultures for tumor cells and T cells were performed to verify the immunomodulatory effect of sitravatinib in tumors.

RESULTS: Sitravatinib showed potent antitumor activity and immunomodulatory capabilities both invitro and in vivo. Sitravatinib treatment synergized with PD-1 blockade to generate an increased antitumor efficacy, leading to significant enrichment of cytotoxic CD8+ T cells and a reduction in the infiltration of regulatory T cells in tumors. Mechanically, on the one hand, sitravatinib reinforced MHC-I expression by blocking the TYRO3-STAT1 axis, thereby sensitizing tumor cells to T-cell killing. On the other hand, sitravatinib suppressed tumor-secreted IL33 by inhibiting TYRO3 activity in HCC cells, resulting in reduced regulatory T-cell differentiation and consequently liberating CD8+ T-cell cytotoxic capacity. In the clinic, one patient with advanced HCC treated with sitravatinib plus PD-1 blockade achieved near-complete response and remained disease progression free for >2 years.

CONCLUSIONS: Collectively, we demonstrated a rationale for combining sitravatinib with PD-1 blockade in the treatment for HCC.

**中文摘要译文：**
目的：酪氨酸激酶抑制剂与免疫检查点阻断剂联合使用，在晚期肝细胞癌（HCC）的治疗中可产生增强的抗肿瘤活性。西曲替尼是一种新型多靶点酪氨酸激酶抑制剂，其靶点包括TYRO3、AXL和MERTK受体、c-MET等。本研究旨在探讨西曲替尼在HCC中的抗肿瘤功效和免疫调节活性。

实验设计：使用人HCC细胞系和异种移植模型来探索西曲替尼的抗肿瘤活性。使用皮下和原位免疫功能健全的鼠HCC模型来评估西曲替尼与PD-1阻断联合治疗的疗效。通过肿瘤细胞与T细胞的共培养来验证西曲替尼在肿瘤中的免疫调节作用。

结果：西曲替尼在体外和体内均显示出强大的抗肿瘤活性和免疫调节能力。西曲替尼治疗与PD-1阻断产生协同作用，提高了抗肿瘤疗效，导致肿瘤中毒性CD8+ T细胞显著富集，调节性T细胞浸润减少。从机制上看，一方面，西曲替尼通过阻断TYRO3-STAT1轴来增强MHC-I的表达，从而使肿瘤细胞对T细胞的杀伤作用更敏感。另一方面，西曲替尼通过抑制HCC细胞中的TYRO3活性来抑制肿瘤分泌的IL33，从而减少调节性T细胞的分化，并因此释放CD8+ T细胞的细胞毒性能力。在临床上，一名接受西曲替尼联合PD-1阻断治疗的晚期HCC患者达到了接近完全缓解，并保持无疾病进展超过2年。

结论：总而言之，我们为西曲替尼联合PD-1阻断治疗HCC提供了理论依据。

### 第二部分 AI 大师评价

本研究旨在探索新型多靶点酪氨酸激酶抑制剂西曲替尼在肝细胞癌（HCC）中的抗肿瘤及免疫调节作用。通过一系列体外与体内实验，研究团队揭示了西曲替尼通过靶向TYRO3，一方面增强肿瘤细胞的MHC-I表达，另一方面抑制调节性T细胞分化，从而双重增强CD8+ T细胞的杀伤功能。这项研究不仅为西曲替尼联合PD-1阻断疗法治疗HCC提供了坚实的实验依据和清晰的分子机制，并通过一例临床病例展示了其巨大的转化潜力，具有重要的临床指导价值。

---

速递结束，祝您工作愉快！